

Title	Non-skeletal health effects of vitamin D supplementation: a systematic review on findings from meta-analyses summarizing trial data
Authors	Rejnmark, Lars;Bislev, Lise Sofie;Cashman, Kevin D.;Eiriksdottir, Gudny;Gaksch, Martin;Gruebler, Martin;Grimnes, Guri;Gudnason, Vilmundur;Lips, Paul;Pilz, Stefan;van Schoor, Natasja M.;Kiely, Mairead E.;Jorde, Rolf
Publication date	2017
Original Citation	Rejnmark, L., Bislev, L. S., Cashman, K. D., Eiríksdottir, G., Gaksch, M., Grübler, M., Grimnes, G., Gudnason, V., Lips, P., Pilz, S., van Schoor, N. M., Kiely, M. and Jorde, R. (2017) 'Non-skeletal health effects of vitamin D supplementation: a systematic review on findings from meta-analyses summarizing trial data', PLOS ONE, 12(7), e0180512 (39pp). doi:
Type of publication	Article (peer-reviewed)
Link to publisher's version	http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0180512 - 10.1371/journal.pone.0180512
Rights	© 2017, Rejnmark et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. - https://creativecommons.org/licenses/by/4.0/
Download date	2026-10-10 08:00:36
Item downloaded from	https://hdl.handle.net/10468/4795


RESEARCH ARTICLE

Non-skeletal health effects of vitamin D supplementation: A systematic review on findings from meta-analyses summarizing trial data

Lars Rejnmark^{1*}, Lise Sofie Bislev¹, Kevin D. Cashman², Gudny Eiríksdóttir³, Martin Gaksch⁴, Martin Gröbler^{4,5}, Guri Grimnes⁶, Vilmondur Gudnason^{3,7}, Paul Lips⁸, Stefan Pilz⁴, Natasja M. van Schoor⁹, Mairead Kiely², Rolf Jorde⁶

1 Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark, **2** Cork Centre for Vitamin D and Nutrition Research, School of Food and Nutritional Sciences, University College Cork, Cork, Ireland, **3** Icelandic Heart Association, Kopavogur, Iceland, **4** Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria, **5** Swiss Cardiovascular Centre Bern, Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland, **6** Tromsø Endocrine Research Group, Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway, **7** Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland, **8** Department of Internal Medicine, Section of Endocrinology, Vrije University Medical Center, Amsterdam, Netherlands, **9** Amsterdam Public Health Research Institute, Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, Netherlands

* lars.rejnmark@rm.dk



OPEN ACCESS

Citation: Rejnmark L, Bislev LS, Cashman KD, Eiríksdóttir G, Gaksch M, Gröbler M, et al. (2017) Non-skeletal health effects of vitamin D supplementation: A systematic review on findings from meta-analyses summarizing trial data. PLoS ONE 12(7): e0180512. <https://doi.org/10.1371/journal.pone.0180512>

Editor: Andrzej T Slominski, University of Alabama at Birmingham, UNITED STATES

Received: May 14, 2017

Accepted: June 18, 2017

Published: July 7, 2017

Copyright: © 2017 Rejnmark et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper and its Supporting Information files.

Funding: This project has received funding from the European Community's Seventh Framework Programme (FP7/2007-2013) under grant agreement 613977 for the ODIN Integrated Project [Food-based solutions for optimal vitamin D nutrition and health through the life cycle, <http://www.odin-vitd.eu/>].

Abstract

Background

A large number of observational studies have reported harmful effects of low 25-hydroxyvitamin D (25OHD) levels on non-skeletal outcomes. We performed a systematic quantitative review on characteristics of randomized clinical trials (RCTs) included in meta-analyses (MAs) on non-skeletal effects of vitamin D supplementation.

Methods and findings

We identified systematic reviews (SR) reporting summary data in terms of MAs of RCTs on selected non-skeletal outcomes. For each outcome, we summarized the results from available SRs and scrutinized included RCTs for a number of predefined characteristics. We identified 54 SRs including data from 210 RCTs. Most MAs as well as the individual RCTs reported null-findings on risk of cardiovascular diseases, type 2 diabetes, weight-loss, and malignant diseases. Beneficial effects of vitamin D supplementation was reported in 1 of 4 MAs on depression, 2 of 9 MAs on blood pressure, 3 of 7 MAs on respiratory tract infections, and 8 of 12 MAs on mortality. Most RCTs have primarily been performed to determine skeletal outcomes, whereas non-skeletal effects have been assessed as secondary outcomes. Only one-third of the RCTs had low level of 25OHD as a criterion for inclusion and a mean baseline 25OHD level below 50 nmol/L was only present in less than half of the analyses.

Competing interests: The authors have declared that no competing interests exist.

Conclusions

Published RCTs have mostly been performed in populations without low 25OHD levels. The fact that most MAs on results from RCTs did not show a beneficial effect does not disprove the hypothesis suggested by observational findings on adverse health outcomes of low 25OHD levels.

Introduction

In recent years the number of studies exploring effects of vitamin D beyond its well-known effects on the musculo-skeletal system have increased markedly. The vitamin D receptor (VDR) and the enzyme (the 1α -hydroxylase) needed to hydroxylate 25-hydroxyvitamin D (25OHD) to its active form 1,25-dihydroxyvitamin D (1,25(OH) $_2$ D) has been identified in a large number of different cells. This widespread expression of the 1α -hydroxylase suggests that local production and action of 1,25(OH) $_2$ D to regulate VDR-directed gene expression may be of importance to the function of many tissues [1]. Moreover, gene array studies have shown that vitamin D may be involved in the regulation of as much as 5% of the human genome [1–3].

Studies in different populations from around the world have shown a high prevalence of vitamin D insufficiency, and observational studies have described associations between low circulating levels of 25OHD and a large number of diseases, including cardiovascular diseases (CVD), malignancies, diabetes, obesity, infections, neuropsychiatric, and autoimmune diseases [4–16].

As causality should not be inferred from observational studies, there is a strong need for clinical and population based trials. So far, only relatively few randomized clinical trials (RCT), specifically designed to assess effects of vitamin D on non-skeletal outcomes, have been performed. Nevertheless, the number of papers published on potential causal effects of vitamin D supplementation is rapidly growing as findings from previously published RCTs, originally designed to evaluate skeletal effects, are being reanalysed in order to elucidate possible non-skeletal outcomes. In evidence-based medicine, results from systematic reviews (SR) of RCTs are considered as the highest level of evidence [17]. Within the last few years, an increasingly number of SRs has been published, including meta-analyses (MAs) with summary data on results from RCT on non-skeletal outcomes in response to supplementation with vitamin D [18–20]. In this paper, our aim is to provide a comprehensive umbrella review on SRs reporting MAs with summary results on clinically relevant non-skeletal outcomes from trials on vitamin D supplementation. In addition, we report characteristics of the individual trials included in MAs, in order to review the evidence-base providing data for published MAs.

Methods

The present paper is a part of a collaborative study between a number of European research institutions within a project on *food-based solutions for eradication of vitamin D deficiency and health promotion throughout the life cycle* (ODIN project, www.odin-vitd.eu) funded by the European Commission as part of the Seventh Framework Programme of the European Community for Research, Technological Development and Demonstration Activities.

At a consensus meeting in Tromsø, Norway, we decided which outcomes to study. Criteria for selecting studied outcomes were:

1. Non-skeletal effects of supplementation with vitamin D in terms of either vitamin D2 (ergocalciferol) or vitamin D3 (cholecalciferol) have been investigated in at least two randomized trials.
2. At least one MA published in which findings from RCTs has been summarized.
3. Outcomes should cover different organ systems and be of clinical importance to European citizens i.e., outcomes on biomarkers were not considered.
4. Reviews should be published in English

Based on these criteria, we selected to study effects of vitamin D supplementation in trials on CVD, blood pressure, type 2 diabetes (T2D), body weight, birth weight, malignant diseases, respiratory tract infections (excluding tuberculosis), depression, and mortality.

We searched PubMed, Embase, and the Cochrane Library until December 1st, 2016 for SRs published in English within the last 10 years on findings from RCTs testing effects of vitamin D supplementations on the selected outcomes. The search strings used are detailed in the supplementary file ([S1 File](#)).

In addition, we manually searched references cited in the papers as well as papers citing the selected papers for additional articles. We only included SRs reporting summary data in terms of MAs. Only MAs on effects of treatment with calciferol (vitamin D2 or D3) were considered. However, we also accepted MAs including RCTs on activated vitamin D analogues in their summary estimate, as long as the majority (>50%) of included studies were on calciferol. In addition, we included a trial on effects of vitamin D supplementation on birth weight although published outside the predefined time range as this SR reports important information on potential bias in a previously published trial [21]. While writing the paper, a large MA on effects of vitamin D supplementation on risk of respiratory infections was published in February 2017 [22]. Although being published after the end of the time period defined *a priori*, we decided to include this paper, as it is the largest MA published so far on vitamin D and infections. A flow chart showing the search profile is shown in [Fig 1](#).

For each MA we assessed its quality using the AMSTAR tool for which the quality is measured on a scale between 0 to 11 [23]. A total score of 9–11 is considered as ‘good’ quality, whereas a score of 5–8 shows ‘moderate’ quality and a score of 0–4 indicates a ‘poor’ quality [24]. Furthermore, for each MA we scrutinize the original papers included in the summary estimate on studied outcomes. Specific characteristics of the individual trials were systematically identified, including the population studied and whether (if relevant) subjects were diagnosed with the disease in question. We also collected information on type of vitamin D studied, dosing frequency, duration of the intervention, and whether calcium was co-administered. Furthermore, we noted whether only participants with low 25OHD levels were included (defined as 25OHD < 50 nmol/L). Finally, we retrieved information on baseline 25OHD levels and whether the intervention resulted in a more than 50% increase in 25OHD levels, as well as the main finding (conclusion) of the trial. We did not perform new MAs, but summarized the characteristics in tables in order to allow for a quantitative evaluation of characteristics of the studies forming the evidence base for published MAs.

Results

We identified 54 SRs reporting summary data in terms of a formal MA on effects of vitamin D supplementation on selected outcomes ([Table 1](#)). Included SRs had a mean AMSTAR score of 8.8 (range 6–11) suggesting an overall moderate to good quality. Within each group of studied non-skeletal health outcomes, mean AMSTAR score varied between 8.4 to 9.8 ([Table 1](#)). For

each outcome, number of RCTs included in one or more of the MAs varied from four to 69 trials. A total of 210 RCTs were included in the MAs.

Cardiovascular diseases (CVDs)

A number of observational studies have reported an inverse association between 25OHD concentrations and risk of CVDs [25–27], including a greater carotid intima–medial thickness




Fig 1. PRISMA flow diagram.

<https://doi.org/10.1371/journal.pone.0180512.g001>

Table 1. Summary characteristics of meta-analyses and the individual RCTs included in MA on non-skeletal effects of vitamin D supplementation.

	CVD	BP	T2D	Body Weight	Birth Weight	Cancer	RTI	Dep.	Death	ALL
Number of meta-analyses	7	9	1	3	6	5	7	4	12	54
<i>Results (main finding)</i>										
Beneficial response	0	2	0	0	2	0	3	1	8	16
Harmful	0	1	0	0	1 ^{a)}	0	0	0	0	2
Null finding	7	6	1	3	3	5	4	3	4	36
AMSTAR Score, mean	8.4	8.9	9	8.3	9.8	9.2	9.8	8.5	9.2	8.8
Number randomized clinical trials	21	59	4	32	14	19	30	12	59	210 ^{b)}
<i>Results (main finding)</i>										
Beneficial response	0	8	0	2	4	1	9	3	0	27
Harmful	0	0	0	1	0	0	1	0	2	4
Null finding	21	51	4	29	10	18	20	9	57	219
<i>Disease studied was primary outcome?</i>										
Yes	0	15	1	5	5	0	23	4	0	53
No	21	44	3	27	9	19	7	7	59	196
Not reported	0	0	0	0	0	0	0	1	0	1
<i>Gender</i>										
Only women	13	12	1	14	14	11	2	4	26	97
Only men	0	1	0	2	0	1	1	0	1	6
Men and women	8	46	3	16	0	7	27	8	32	147
<i>Number of included participants</i>										
<1000	15	58	2	31	14	13	28	9	43	213
≥ 1000	6	1	2	1	0	6	2	3	16	37
<i>Characteristics of participants</i>										
Diagnosed with the disease studied	1	7	1	11	NA	0	11	3	NA	34
Not diagnosed with the disease	20	52	3	21	NA	19	19	9	NA	143
<i>Vitamin D supplements used.</i>										
Vitamin D3	13	56	4	29	9	15	30	11	43	86
Vitamin D2	2	3	0	2	4	1	0	0	12	17
Calciferol (D2/D3) ^{b)}	1	0	0	0	1	0	0	0	3	5
Activated vitamin D	5	0	0	1	0	3	0	1	1	13
<i>Frequency of vitamin D administration</i>										
Single dose	0	6	0	0	3	0	1	1	2	13
Daily	17	29	3	23	4	14	16	7	39	152
Less than daily	4	24	1	9	7	5	13	4	18	85
<i>Co-administration of calcium</i>										
No	9	47	1	18	10	11	29	8	27	160
Only to the vitamin D group	5	4	2	5	2	5	0	2	24	49
Both vitamin D and control group	7	8	1	9	2	3	1	2	8	41
<i>25OHD < 50 nmol/L as inclusion criteria</i>										
No	19	8	4	26	14	18	29	11	54	183
Yes	2	51	0	6	0	1	1	1	5	67
<i>Mean 25OHD levels at baseline</i>										
< 50 nmol/L	7	37	1	15	5	8	7	5	27	112
≥ 50 nmol/L	6	18	2	11	1	9	13	3	16	79
Not reported	8	4	1	6	8	2	10	4	16	59
<i>Duration of follow-up</i>										
< 1 year	1	50	1	16	NA	4	18	8	19	117
≥ 1 year	20	9	3	16	NA	15	12	4	40	119
<i>Mean changes in P-25OHD levels compared with baseline:</i>										
< 50% increase	4	15	2	15	2	8	10	3	23	82
≥ 50% increase	6	37	1	12	4	7	9	5	17	98
Not reported	11	7	1	5	8	4	11	4	19	70

NA: not appropriate; Dep: depression.

a)Strong suspicion that data from one of the studies included in the MA were wrongly stated in the published paper (see text in section on birth weight)

b)Some RCTs were included in more than one MA, why total number of RCT within the row do not sum up to N = 210

<https://doi.org/10.1371/journal.pone.0180512.t001>

[28], peripheral arterial disease [29], and risks of cardiovascular (CV) death [30,31]. Moreover, MAs on data from observational studies have consistently found an increased risk of CVD in subjects with vitamin D insufficiency [32,33]. An effect of vitamin D on CV health is further-more biologically plausible, as the 25OHD-1 α -hydroxylase enzyme is expressed by CV tissues and the VDRs have been identified in vascular smooth muscle cells, cardiomyocytes, as well as in coronary arteries [34–36]. Given the presence of the VDR in the vascular system, vitamin D may potentially improve CV health through several biological pathways. For example, activation of the VDR has been shown to inhibit vascular smooth muscle cell proliferation, which is believed to be cardio-protective [37,38]. Moreover, a state of chronic inflammation is considered to play a key role in the initiation and progression of CVD [39,40], and several studies have shown an inverse association between 25OHD levels and markers of inflammation, suggesting that vitamin D also may protect against CVD by lowering the state of inflammation [41–43]. On the other hand, trials assessing the effects of vitamin D supplementation on arterial stiffness, a marker of cardiovascular risk, have shown ambiguous results. In a MA including data from seven RCTs involving a total of 547 participants, supplementation with vitamin D3 for 2 to 12 months showed no significant effects on changes in pulse wave velocity [44]. Nor did a MA including data from seven RCTs suggest beneficial effects of vitamin D supplementation on left ventricular function or exercise tolerance [45].

We identified 10 SR among which seven reported summary data for incident CVDs in terms of formal MAs, whereas three SRs considered the interventions and outcomes in published RCTs to be too heterogeneous for MA [36,46,47]. Table Aa in [S1 File](#) shows the seven SRs reporting pooled data on results from RCTs on effects of vitamin D supplementation on risk of CVDs [48–54]. None of the MAs showed neither beneficial nor harmful effects on estimates in response to the interventions on risk of CVDs, in terms of any CV events, myocardial infarctions (MI), stroke/ cerebrovascular disease, or CV death (Table Aa in [S1 File](#)). In several of the MAs summary risk estimates were stratified by whether vitamin D was provided alone or in combination with calcium (CaD), showing no effects of any of the interventions. Only one of the seven MAs addressed whether supplementation to individuals with low vitamin D levels may result in beneficial effects on cardiovascular health, showing no significant interaction when comparing risk estimates from studies with mean 25OHD levels below vs. above 50 nmol/L on stroke ($P_{\text{interaction [Pi]}} = 0.36$) or myocardial infarction ($P_i = 0.83$) [49]. Neither did interaction analyses suggest differences according to whether the intervention resulted in increased (unspecified) 25OHD levels on risk of stroke ($P_i = 0.41$) or myocardial infarction ($P_i = 0.34$) [49].

Numbers of RCTs included in each MA varied from two to 11 RCTs, and the total number of randomized participants included in the RCTs varied between 2,988 and 48,647. The seven MAs included data from a total of 21 RCTs (Table Ab in [S1 File](#)), among which 16 were on effects of treatment with calciferol and five on treatment with activated vitamin D analogues. Only the study by Trivedi et al. [55] was included in all seven MAs, whereas two trials were included in six of the MAs.

Summary characteristics of the 21 RCTs are shown in [Table 1](#). None of the trials had pre-specified CVD as their primary outcome. Most of the trials included only women, and none of the RCTs studied only men. Six of the RCTs were large-scale studies with more than 1000 participants. Only one of the trials included participants recruited based on cardiovascular risk factors in terms of systolic hypertension [56]. Thirteen RCTs investigated effects of vitamin D3, two studied effects of vitamin D2 and one study did not report specifically whether the intervention was D2 or D3. In five studies, all included (only) in the MA by Ford et al. [53], effects of activated vitamin D analogues were investigated. In most of the studies, vitamin D was administered as a daily dose and calcium was co-administered in approximately half of the

studies. Only two trials had low 25OHD levels (< 50 nmol/L) as inclusion criteria [57,58], in which 352 participants who received treatment for one-year participated [57,58]. In addition, four RCTs reported mean 25OHD levels at baseline below 50 nmol/L [56,59–61], in which approximately 8000 participants were randomized to treatment for one to five years. Among the 16 trials investigating effects of vitamin D2 or D3, only four reported an increase in 25OHD levels of more than 50% in response to the treatment. None of the included RCTs reported neither beneficial nor harmful effects on risk of CVDs in response to the interventions. While writing this review, we noticed that findings from a large RCT (one of the so called ‘mega-RCTs’) were published on effects of vitamin D treatment on risk of CVD in the general population as primary endpoint. In the study, Scragg et al [62] randomized 5110 participants (42% females) to receive placebo ($n = 2552$) or vitamin D3 ($n = 2558$) with an initial dose of 200,000 IU, followed a month later by monthly doses of 100,000 IU, for a median of 3.3 years. The study showed no beneficial effects of vitamin D supplementation on risk of CVD (hazard ratio [HR] 1.02; 95% confidence interval [CI] 0.87 to 1.20). The study population had a mean (SD) baseline deseasonalized 25OHD concentration of 66 (26) nmol/L and 25% of studied subjects had 25OHD levels below 50 nmol/L at baseline. Similar to the main analysis, sub-analyses on effects of vitamin D supplementation within the group of participants with 25OHD levels below 50nmol/L showed no effects of the intervention.

In summary, a discrepancy seems to exist between findings from observational studies and randomized trials on effects of vitamin D on risk of CVDs. Nevertheless, none of the RCTs included in the MAs have been designed to specifically address whether supplementation with vitamin D affects CV health and available data from secondary analyses are, as reviewed above, characterized by a high degree of heterogeneity. However, the recently published study by Scragg et al [62] with CVD as primary outcome does not support beneficial effects of vitamin D supplementation on risk of CVD. Importantly, whereas observational studies have reported adverse health effects on CV health of low 25OHD levels, only few of the RCTs published have specifically investigated effects in a population with low 25OHD levels.

Blood pressure

A possible link between vitamin D and hypertension has been extensively investigated. Strong observational data associate low 25OHD levels with an increase in blood pressure and an increased risk of hypertension [63–65]. Moreover, a large Mendelian randomization analysis concluded that increased 25OHD levels might reduce risk of hypertension [66]. Vitamin D may control blood pressure through its regulatory effects on the renin–angiotensin–aldosterone system (RAAS) [67,68]. Vitamin D may suppress the renin biosynthesis [67], and human studies have shown increased levels of renin and angiotensin II in subjects with vitamin D deficiency [69,70]. Moreover, a positive correlation has been shown between PTH and angiotensin II/ aldosterone [68,71,72]. Trials with vitamin D supplementation have furthermore shown that vitamin D stimulates various effects on the endothelia, smooth muscle cells, and in macrophages. Such local mechanisms of action on the vessel wall have been suggested to be of importance for blood pressure regulation [73–77].

We identified nine SRs on RCTs reporting effect of vitamin D supplementation on blood pressure [46,49,78,79] [80–84] (Table Ba in S1 File). A significant reduction in SBP (range -6.18 mmHg. to -2.44 mmHg) with no effect on DBP was reported in two of the MAs each including four RCTs with approximately 400 participants [78,79]. In the study by Withham et al. [78] only participants from studies with elevated mean baseline blood pressure were included and effects on blood pressure was designated as the primary outcome. In contrast, in

the MA by Wu et al. [79] studies on patients with hypertension were not considered, but the majority of included participants had, nevertheless, arterial hypertension.

No beneficial effects of vitamin D supplementation were, however, reported in two recent MAs by Beveridge et al [81] and Golzarand et al [83], including 38 and 30 RCTs, respectively. The two MAs included a meta-regression analysis on dose-response effects showing no associations between daily dose (-equivalent) of vitamin D supplementation and changes in BP. Similarly, the MA by Wu et al. (66) showed no dose-response effects. This is in contrast to the MAs published by Pittas et al. (39) showing a beneficial dose-response effect on DBP. In response to a daily dose above 1000 IU, DBP was significantly reduced compared with a daily dose below 1000 IU.

Three MAs have addressed effects of vitamin D in combination with calcium [46,79,83]. Two of the MAs showed no difference in change in SBP and DBP according to whether vitamin D was tested alone or in combination with calcium D, whereas the MA by Golzarand et al [83] found a significantly increase in SBP (3.64 mmHg, 95%CI: 3.15–4.13) and DBP (1.71 mmHg, 95%CI: 1.25–2.18) in response to treatment with CaD.

Two MAs have investigated effects of vitamin D supplementation in specific populations. By pooling results from 15 RCTs on patients with T2D, Lee et al. [84] found no effects of vitamin D on SBP, although DBP was slightly but significantly ($p = 0.02$) reduced (SMD -0.160 (95% CI -0.298 to -0.022) mmHg, $I^2 = 0\%$). In contrast, an increase in SBP (WMD: 0.237; 95% CI, 0.110 to 0.365) was found in a trial level MAs by Manousopoulou et al. [82], including five RCTs on adults with obesity.

Only two of the MAs have investigated whether baseline 25OHD levels are of importance. In the MA by Withham et al. [77], all four studies included reported mean 25OHD level below 50 nmol/L with a summary estimate showing a significantly decreased SBP in response to the intervention. In contrast, a trial-level meta-regression analyses in the SR by Beveridge et al [81] showed no significant effects on responses in blood pressure of baseline 25OHD levels or increases of 25OHD levels in response to supplementation.

The nine MAs included data from 59 RCTs with a total of 42,814 participants. The majority of the participants were from the WHI study, whereas the number of participants ranged from 16 to 511 in the other 58 RCTs (Table 3B in Bb S1 File). The studies have been published between 1983 and 2015. Eight of the RCTs had a duration of one-year or more and none of these studies with long duration showed a reduced BP in response to the intervention.

In 49% of the studies, vitamin D was administered as a daily dose and calcium was co-administered in 12 of the studies. Most trials used oral vitamin D3, but one study [85] reports the effect of UVB vs. UVA radiation and in one study the effect of a single dose vitamin D2 was investigated [86]. Although 25OHD levels below 50 nmol/L was only required as an inclusion criteria in eight (14%) of the studies, mean 25OHD levels at baseline were below 50 nmol/L in 63% of the trials and increased by more than 50% in response to the supplementation in almost two-third of the trials (Table 1).

Overall, eight RCTs reported a beneficial response of vitamin D on blood pressure [85–92], whereas 51 studies found no effects (Table Bb in S1 File). Among the eight studies reporting a beneficial response, two had low 25OHD levels as inclusion criteria [86,87] and six of the trials reported a mean 25OHD level at baseline below 50 nmol/L [85–87]. Furthermore, five of the studies reported a mean increase in 25OHD levels of 50% or more in response to the intervention [85,87,88,90,92]. Type of vitamin D intervention varied widely between the eight studies showing beneficial effects. Three studies used vitamin D in combination with calcium [87,89,91] and one study used UVB exposure [85]. The remaining four studies administered vitamin D using different dosing regimens in terms of a daily dose [90], a weekly dose [92], a single high dose [86], or a 50,000 IU dose of D3 administered twice three weeks apart [88].

The populations studied in the eight trials varied widely. Some studies included patients with mild hypertension, others pregnant women or healthy normotensive persons. In addition, as recently highlighted in a paper by Veloudi et al. [93], only a small proportion of the trials on effects of vitamin D supplementation on blood pressure have actually examined effects in patients with low vitamin D levels. Similarly, we found that only eight of 51 trials (16%) included in published MAs had a 25OHD level below 50 nmol/L as inclusion criterion.

In summary, two of nine published MA and eight of 59 individual RCTs included in the MAs, showed beneficial effect of vitamin D supplementation on BP, whereas one MA found an increase in SBP in obese adults in response to vitamin D supplementation. Overall, these results do not provide substantial support for the findings from the observational studies on an importance of vitamin D on blood pressure regulation. Nevertheless, as most trials on effects of vitamin D supplementation has been performed in populations without low 25OHD levels, the hypothesis raised by observational studies on adverse effects of low vitamin D levels has in reality not been tested to a large extent by trials performed so far.

Diabetes

Numerous observational studies have shown lower 25OHD levels in patients with T2D compared with the general population, as well as an inverse association between 25OHD levels and fasting plasma glucose, impaired glucose tolerance, and HbA1c levels [94–103]. In studies on potential biological actions of vitamin D in relation to glucose homeostasis, vitamin D has been suggested to be of importance to insulin secretion and action. The pancreatic islet cells have been shown to express the VDR as well as the 1α -hydroxylase enzyme, enabling conversion of 25OHD into its active form directly by the β -cells [104,105]. In animal experimental studies, vitamin D deficiency inhibits pancreatic secretion of insulin [106] and vitamin D repletion of rats with vitamin D insufficiency has been shown to improve glucose tolerance and glucose-stimulated insulin release [107,108]. Trials in humans on potential effects of vitamin D supplementation on indices of glucose homeostasis have, however, not demonstrated a clear beneficial effect. Recent MAs on results from RCTs showed no significant improvement on indices of glucose homeostasis including HbA1c levels in those treated with vitamin D compared with placebo [19,109–111]. Restricting study subjects to patients with diabetes or impaired glucose tolerance, one of the MA showed, nevertheless, a small but significant improvement in fasting glucose levels (-0.32 mmol/L, 95% CI, -0.57 , -0.07) and a small improvement in insulin resistance (SMD -0.25 , 95% CI, -0.48 , -0.03) [109]. As these reviews provide a comprehensive update on findings from randomized trials on effects of vitamin D on biochemical indices of glucose homeostasis, we chose to focus on clinical outcomes in terms of effects of vitamin D supplementation on risk of incident T2D.

We identified three SRs on risk of incident T2D in RCTs on vitamin D supplementation [12,112,113]. However, only one of the SRs provided a summary risk estimate based on a MA [12] (Table Ca in S1 File). The MA included data from four RCTs [114–117], and showed no effects of vitamin D supplementation on risk of incident T2D [12]. Stratification by glucose levels at baseline showed no effects on risk of progression in participants with normal glucose levels or in patients with an impaired glucose tolerance at baseline. The SR did not report findings according to baseline levels of 25OHD or changes in 25OHD levels in response to supplementation.

Table Cb in S1 File shows characteristics of the four RCTs included in the MA and characteristics of the RCTs are summarized in Table 1. Only one of the four studies had development of diabetes as a co-primary end-point [117]. This was a small study that included only 109 patients with pre-diabetes [117]. One study included patients diagnosed with pre-diabetes,

whereas two studies included participants from the general population and one study included patients with a previous fracture. None of the studies had low 25OHD levels as a prerequisite for inclusion and mean 25OHD levels at baseline was only below 50 nmol/L in only one of the trials [116]. None of the individual RCTs showed beneficial effects of vitamin D supplementation on risk of incident T2D.

In summary, there is a discrepancy between findings from observational studies and RCTs on effects of vitamin D on risk of T2D. The number of trials is relatively small and the majority of subjects included in the trials did not have low 25OHD levels. Accordingly, the findings from observational studies on an increased risk among those with vitamin D insufficiency cannot be considered as being disproved by data from RCTs.

Body weight/obesity

Obesity has been associated with low levels of 25OHD in a large number of observational studies [118–121]. This may be attributable to different mechanisms. Following endogenous synthesis or dietary intake, vitamin D is readily stored in adipose tissue [122]. As the body pool of fat is larger in obese compared with non-obese individuals, vitamin D may be diluted or sequestered in the larger body pool of fat resulting in lower plasma levels [123]. Moreover, in a study by Wortsman et al. [124], it was found that following endogenous synthesis; the release of vitamin D₃ from the skin into the circulation is decreased in obesity. It has also been suggested that obese subjects are less exposed to sunlight, leading to lower 25OHD levels. This may be due to clothing habits and less involvement in outdoor activities (reduced mobility) resulting in less skin exposure [125]. Finally, a recently published bi-directional Mendelian randomization analysis of multiple cohorts showed that a higher BMI leads to lower plasma 25OHD levels whereas low 25OHD levels did not appear to lead to a high BMI [126].

In contrast to the above reviewed findings, suggesting that low vitamin D levels are a consequence of obesity, findings from a number of other studies have suggested that low 25OHD levels may predispose to obesity. The VDR is expressed by adipose tissue and adipose tissue has the ability to synthesize 1,25(OH)₂D [127,128]. Studies have also suggested that vitamin D may regulate adipose tissue mass, differentiation and metabolism in ways that might contribute to obesity [129]. Furthermore, secondary hyperparathyroidism is a well-known consequence of vitamin D insufficiency and increased PTH levels promote calcium influx into the adipocytes. In adipocytes, intracellular calcium may enhance lipogenesis, and PTH excess may thereby promote weight gain [130,131]. Conflicting results have been reported on the potential anti-inflammatory effects of vitamin D. Obesity is considered as a state of chronic low-grade inflammation [132]. Although several in-vitro and animal experimental studies have suggested anti-inflammatory effects of vitamin D in obesity, results from human intervention studies have not shown effects on inflammatory cytokines in response to vitamin D supplementation [133–135].

In our search for SRs reporting effects of vitamin D supplementation on changes in body weight, we identified four SRs [82,136–138] among which three provided summary data in terms of a formal MA including data from 32 RCTs (Table Da in S1 File). Overall, the MAs showed no effects of vitamin D supplementation on changes in body weight, fat mass (FM), percentage FM (%FM), or lean body mass. Only the MA by Chandler et al. [138] showed a beneficial effect on weight loss of supplementation with CaD as compared to placebo.

Table Db in S1 File shows characteristics of the 32 RCTs included in the MA and summary characteristics of the trials are shown in Table 1. The 32 RCTs have been published between 1987 and 2014. One of the trials included in the MA by Chandler et al. [138] reported effects on treatment with active vitamin D [139], whereas the other 31 trials reported effects of

treatment with vitamin D2 (2 RCTs) or D3 (29 RCTs). The majority of the individual trials reported null-findings. Only two trials found beneficial effects of supplementation [139,140]. In the WHI trial, a secondary analysis on weight changes showed that women randomized to the CaD group had smaller average annual weight gains than women assigned to the placebo group [140]. In contrast, Maki et al. [141] reported a significantly increased body weight in response to eight weeks of treatment with a daily multivitamin and mineral supplement containing D3 1,200 IU D3/d compared with the same supplement without D3. Weight loss was a primary endpoint in five of the trials [142–146] and none of these showed beneficial effects of vitamin D intervention. Most of the studies assessed effects in both men and women (N = 16 trials). Number of subjects included was less than 1000 in all of the trials except for the WHI trial [140]. Eleven (34%) of the trials included participants with (signs of) obesity, none of them showing beneficial effects of supplementation.

Six (19%) of the studies had low 25OHD levels (<50 nmol/L) at baseline as a criterion for inclusion, but mean 25OHD levels were below 50 nmol/L in almost half of the studies (N = 15) and 25OHD levels increased by more than 50% in N = 15 (47%) of the trials in response to the intervention (Table 1). Only one of the MAs have addressed the importance of 25OHD levels, showing no effects of either 25OHD levels archived in response to supplementation nor change in 25OHD levels from baseline in meta-regression analyses on obesity measures [137].

In summary, an inverse association between body weight and 25OHD levels is well documented. While it is generally agreed that obesity results in low 25OHD levels, it is still disputed whether low 25OHD levels may contribute to weight gain. Although most of the individual RCTs included in the MAs were relatively small in terms of number of participants and of short duration, the studies did, nevertheless, investigate effects of vitamin D supplementation in populations in which mean 25OHD levels were below 50 nmol/L, as well as 25OHD levels increased by more than 50% in approximately half of the studies. Accordingly, trial data do not support a beneficial effect of vitamin D supplementation on weight loss.

Birth weight

Vitamin D insufficiency is common in pregnant women [147–149], and a number of studies have investigated effects of vitamin D status on pregnancy outcomes. Results from three SRs on findings from observational studies, suggest a reduced birth weight in infants born by mothers with low 25OHD levels [18,150,151]. In a MA by Aghajafari et al. [150] a significantly lower birth weight (weighted mean difference –131g; 95% CI, –187g to –75g) was found in infants born by mothers with 25OHD levels below 37.5 nmol/L during pregnancy. The MA also showed a significant inverse association between low 25OHD levels and risk of small gestational age (SGA) infants (OR 1.85; 95% CI, 1.52 to 2.26), as well as risk of gestational diabetes, pre-eclampsia, and bacterial vaginosis [150]. Similar findings were reported in a SR by Wei et al. [151], in which a MA of observational data showed an increased risk of SGA infants (OR 1.52, 95% CI, 1.08 to 2.15) if maternal 25OHD levels were below 50 nmol/L during pregnancy. Moreover, in an umbrella review of SRs, Theodoratou et al. [18] reported concordant results from MA of observational studies and randomised trials, suggesting an increased birth weight with improved vitamin D status.

Several biological mechanisms responsible for potential effects of vitamin D on fetal development have been suggested, including an importance of vitamin D on placental development through effects on human chorionic gonadotropin expression and placental sex steroid synthesis [152]. Moreover, an increased expression of 1 α -hydroxylase and VDR in early pregnancy trophoblast and decidua tissue has been reported, suggesting an importance of vitamin D in early foetal development [153].

In our search for SRs on effects of vitamin D supplementation on birth weight, we identified eight SR [21,113,154–158] among which six [21,154,155,157–159] reported MAs on pooled data from RCTs on effects of vitamin D supplements on weight of new-born infants (Table Ea in S1 File). Three of the MAs were Cochrane reviews which have been continuously updated [21,155,159]. In the first of the published MA, Mahomed et al. [21] found a reduced birth weight in response to vitamin D supplementation in a daily dose of 1000 IU/d. However, this was based on data from two studies with a total of only 176 pregnant women. In one of the studies, the reported SD of mean birth weight was very low (reported to be 70–90g) whereas it normally is approximately 600 g [160]. It is likely that the standard error was reported instead of SD and this may have affected the pooled estimate of the MA. Accordingly, the authors of the MA conclude that too few data were available to draw conclusions on effects of supplementation on birth weight [21]. In the other five MAs, two showed an increased birth weight in response to vitamin D supplementation [158,159], whereas three reported null findings [154,155,157] (Table Ea in S1 File). In one of the SR, data were stratified by dose of vitamin D supplementation [157], showing no effects on birth weight in neither studies using high doses nor studies using low doses (Table Ea in S1 File).

The six MAs included data from 14 RCTs. Table Eb in S1 File shows characteristics of the individual trials included in the MAs and characteristics of the individual trials are summarized in Table 1.

Overall, four of the individual trials reported beneficial effects of the supplementation, whereas 10 RCTs reported null-findings. Birth weight/fetal growth was considered as a (co-) primary endpoint in three of the four studies reporting beneficial effects of supplementation [161–163]. The number of pregnant women included in the 14 trials varied from 50 to 350. In most studies, vitamin D supplementation was initiated in the 3rd trimester, as only a few studies started the supplementation in the 2nd trimester [163–166].

Supplementation with vitamin D3 was used in most trials (N = 9), and in three of the four trials showing beneficial effects on birth weight. All four studies showing a beneficial effect used high dose treatment in the 3rd trimester either as a single high dose or high doses given 2–3 times. All of the four studies were performed as open label trials in non-western countries (three in India and one in Iran).

None of the studies had vitamin D insufficiency (25OHD < 50 nmol/L) as criteria for inclusion, and eight of the trials did not report 25OHD levels at baseline or changes in response to supplementation. None of the four studies showing beneficial effects reported changes in 25OHD levels in response to treatment and only one of the four studies reported baseline 25OHD levels. None of the published MAs, reported effects according to baseline 25OHD levels or changes in 25OHD levels.

Only the studies by Brooke et al. [167] and Hollis et al. [164] reported a 50% increase in 25OHD levels in response to treatment. The study by Brooke et al. [167] had, however, a rather small sample size whereas the study by Hollis et al. [164] had a reasonable sample size and used a relatively high vitamin D dose although including women who did not have vitamin D insufficiency (Table Eb in S1 File).

In summary, in contrast to findings from observational studies, results from most RCTs have not shown beneficial effect of vitamin D supplementation on birth weight. The quality of the trials showing an increased birth weight in response to supplementation is limited by the lack of blinding and measurement of 25OHD levels. Accordingly, available data from RCTs on effects of vitamin D supplementation on birth weight do not clearly support findings from observational studies. Of notice, the sample size in most trials have been relatively small and in most of the studies, the intervention has been of short duration and initiated in late pregnancy, whereas several observational studies showing an inverse association between 25OHD levels

and birth weight have assessed vitamin D status in early/mid pregnancy [168]. Accordingly, the hypothesis raised by findings from observational studies on effects of vitamin D status on birth weight has not been properly tested in RCTs.

Malignant diseases

A potential antineoplastic effect of vitamin D has been suggested by findings from *in vitro* studies, as vitamin D may affect several cellular processes, including proliferation, differentiation, angiogenesis, and apoptosis [169,170]. Although an association between vitamin D and risk of cancer has not been found in all human studies, several observational studies have reported an inverse association between risk of cancer and a low dietary intake of vitamin D, a low degree of sun exposure, or low plasma levels of 25OHD [171–173]. Studies on VDR polymorphisms (BsmI, TaqI, FokI, and ApaI) [174,175], and MAs on data from observational studies also support an association between low 25OHD levels and an increased risk of malignant diseases [176–180] as well as cancer mortality [181].

We identified eight SRs reporting data from RCT on risk of incident malignant diseases in response to vitamin D supplementation [52,54,113,182–186]. However, a formal MA reporting summary risk estimates was only performed in five of the SRs [52,54,184–186] (Table Fa in [S1 File](#)).

Following the Evidence/Technology Assessment report on health outcomes of vitamin D and calcium published in 2009 by Chung et al. [182], Chung and colleagues [183] published an update in 2011 on cancer outcomes. The SR reports data from three RCTs [55,187,188], but no pooled summary estimates are reported. The SR concludes that the available data do not allow for any firm conclusions on harm or benefits of vitamin D supplementation for cancer prevention. Moreover, in a SR on non-skeletal effects of vitamin D by Rosen et al [113], commissioned by The Endocrine Society, data from three RCTs are reviewed. The three studies included are similar to those reviewed by Chung et al [183]. No formal MA was performed. In accordance with the conclusion by Chung et al [183], Rosen et al [113] conclude that there is not sufficient evidence to draw conclusions on whether vitamin D may affect cancer incidence or mortality from cancer. However, the paper did not consider a prior analysis performed by Bolland et al. [189] showing an interaction between use of personal CaD supplements and randomization to CaD vs. placebo in the WHI trial. The analysis showed a significantly decreased risk of breast cancers and a non-significantly reduced risk of colorectal cancer in women randomized to CaD supplementation who did not take personal CaD supplements at randomization [189].

In a SR commissioned by the U.S. Preventive Services Task Force (USPSTF), aiming at updating the evidence on benefits and harms of vitamin and mineral supplementation to prevent cancer, Fortmann et al. [52] and Keum et al. [186] performed MAs on data from four RCTs on primary prevention of cancers in the general adult population. None of the analyses showed effects of vitamin D supplementation on risk of incident cancers, and this was not changed by stratification on whether the supplementation was provided as vitamin D alone or vitamin D in combination with calcium (Table Fa in [S1 File](#)).

Bjelakovic et al [184] published an elaborated Cochrane review including data from 18 RCTs on risk of incident cancers and cancer mortality. In the SR, a number of MAs were performed showing no significant effects of vitamin D supplementation on risk of developing cancer. However, based on data from four studies, the MA showed a significantly reduced risk on cancer mortality (RR 0.88; 95% CI, 0.78, 0.98). Similarly, a reduced risk of death due to malignancies (RR 0.88; 95% CI, 0.79–0.98, $p = 0.03$, I^2 0%) was also been reported in MAs by Zheng et al. [190] and Keum et al. [186], both pooling findings from three trials [55,188,191] with a total of 44,260 randomized participants.

In another SR, Bolland and colleagues [54] identified SRs published since 2009 that summarized data from RCTs on effects of vitamin D supplementation on risk of cancer. Three MAs were identified including seven RCT [182,183,192]. Bolland et al. [54] performed a new MA, based on data from the seven RCTs included in these three SRs. The new MA showed no effects of vitamin D supplementation, either alone or in combination with calcium, on risk of incident cancers (Table Fa in S1 File).

In addition, Sperati et al [185] performed a SR focusing specifically on effects of vitamin D on risk of breast cancer. The authors identified only two studies fulfilling their pre-defined criteria for inclusion of studies (Table Fa in S1 File). The MA showed no beneficial effects of vitamin D supplementation and neither was vitamin D dosage nor mode of administration found to affect risk of breast cancer [185].

Table Fb in S1 File shows characteristics of the 19 RCT included in the five MA and Table 1 summarizes characteristics of the individual studies.

None of the RCTs assessed risk of cancer as a primary outcome. The majority of the studies was performed in women-only (58%) with less than 1000 randomized participants (68%) and no RCT included in published SRs provides data on effects of vitamin D supplementation in patients already diagnosed with cancer. Mean levels of 25OHD at baseline were below 50 nmol/L in less than half of the studies and only one study had low 25OHD levels as an inclusion criteria. Only one of the MAs addressed whether vitamin D status at baseline is of importance to responses, showing no difference in risk of incident cancers between trials with mean baseline levels below 50 nmol/L (RR 0.99; 95% CI, 0.93–1.05) compared with studies with mean 25OHD levels above 50 nmol/L (RR 1.12; 95% CI, 0.94, 1.34) [184].

The majority of studies investigated effects of vitamin D₃ administered as a daily supplement. The MA by Bjelakovic et al [184], also included data from three studies on treatment with activated vitamin D analogues. More than half of the studies investigated effects of vitamin D alone, whereas calcium was co-administered in seven studies to either only the vitamin D group (5 RCT) or to both the vitamin D and the control group (3 RCT). Most of the studies (79%) had a duration of at least one year. The intervention with vitamin D supplementation increased plasma 25OHD levels by more than 50% in only one-third of the studies. Only one of the 19 RCTs showed a reduced incidence of cancers in response to supplementation with vitamin D. This study was performed by Lappe et al [187] and did not have malignant diseases as a primary outcome (Table Fb in S1 File). Most recently, Lappe et al [193] have published results from a subsequent double-blind RCT comparing effect of four-years of treatment with a daily supplement of D₃ 2000 IU plus 1500 mg of calcium with placebo on risk of incident all-type cancer (primary endpoint). The trial included 2,303 healthy elderly women with a mean age of 65±7 years and a mean baseline 25OHD level of 82±26 nmol/L. The study showed no significant beneficial effects on cancer incidence (HR 0.70; 95% CI, 0.47 to 1.02). However, the study probably had a too low statistical power to show such an effect [194].

Conclusions: MAs on results from RCTs on effects of vitamin D supplementation on risk of cancer have concluded that no evidence exists to support a causal relationship. It should, however, be emphasized that most RCTs included in the SRs have been carried out in groups of participants without low 25OHD levels and mean changes in 25OHD levels in response to supplementation have either not been assessed or been less than 50% of baseline values in most studies. In addition, the duration of the intervention has in most studies been rather short. Interestingly, the WHI study [189] as well as the trials by Lappe et al [187,187] had a relatively long duration and did suggest beneficial effects. More so, data on specific types on malignant diseases are largely missing. Accordingly, the evidence-base by which the MAs are grounded does not seem to be appropriate to reject the findings from observational studies on an increased risk of cancer in vitamin D insufficiency.

Respiratory tract infections

For more than a century, vitamin D deficiency has been suggested to increase the susceptibility to infection. Early observations showed increased risk of respiratory tract infections (RTI) in children with nutritional rickets and vitamin D was considered of importance in the treatment of tuberculosis [195,196]. The seasonality of RTIs such as those caused by rhinovirus (“common cold”) and influenza virus is well known, and low 25OHD levels during wintertime have been suggested to be the “seasonal stimulus” which increases the susceptibility to such infections [197]. If so, this is of major importance to public health, as RTI are a major contributor to mortality [198,199]. Recent studies have provided further evidence of vitamin D as an important regulator of human immune function, as vitamin D may stimulate the innate immune response which provides front-line protection against infectious agents [200]. The VDR has been shown to be expressed in different cells of the myeloid and lymphoid lineage and vitamin D may increase the expression of antimicrobial peptides in human monocytes and neutrophils [201,202]. Particularly, vitamin D may enhance the expression of the human cathelicidin antimicrobial peptide (hCAP-18) which is of specific importance in host defenses against respiratory tract pathogens [203]. In accordance with the findings from epidemiological and *in-vitro* studies, a number of observational studies have suggested an inverse association between vitamin D status and risk of infections. Thus, risk of a recent RTI was significantly increased by 24% among participants with low compared with high 25OHD levels (below/above 75 nmol/L) in the Third National Health and Nutrition Examination Survey in the USA, which included 18,883 study subjects [204]. Similarly, an inverse association between vitamin D status and risk of developing RTIs has also been reported in other cohorts as well as a replete vitamin D status has been associated with fewer days of absence from duty due to RTIs [205–209].

In our search for SRs on effects of vitamin D supplementation on risk of RTIs, we identified 10 SR [22,210–218] among which seven [22,211–213,216–218] reported MAs on pooled data from RCTs on risk of RTIs in response to vitamin D supplementation (Table Ga in S1 File). In two trial-level MAs, vitamin D supplementation was found to significantly reduce risk of RTI by approximately 40% [211,212], which also applied to pediatric populations [211]. The first of the trial MA found a protective effect by summarizing data from five RCTs [211], the second trial MA included data from 11 RCTs [212]. A subsequent trial-level MA by Mao et al [213], however, found no beneficial effects of vitamin D supplementation on risk of RTI. Mao et al [213] included only data from seven RCTs, as this MA excluded studies which were considered to be of low quality in terms of a modified Jadad score ≤ 3 [219]. Most recently, an individual patient data analysis (IPD) has been published, including individual data from 10,933 study subjects included in 25 RCTs [22]. The analysis showed a significantly reduced risk of acute RTI (OR 0.88, 95% CI, 0.81 to 0.96). Sub-group analyses suggested protective effects in response to a daily or weekly vitamin D dose (adjusted odds ratio 0.81, 0.72 to 0.91), but not in response to one or more bolus doses (adjusted OR 0.97, 95% CI, 0.86 to 1.10; $P_i = 0.05$). Moreover, among those receiving daily or weekly vitamin D, the protective effects were stronger in those with a baseline 25OHD < 25 nmol/L (adjusted OR 0.30, 95% CI, 0.17 to 0.53) than in those with a baseline 25OHD ≥ 25 nmol/L (adjusted OR 0.75, 95% CI, 0.60 to 0.95; $P_i = 0.006$) [22]. However, two of the other published MAs found no differences between studies with mean baseline levels above or below 75 nmol/L [212] or 50 nmol/L [218].

The seven MAs included data from a total of 30 RCTs. Table Gb in S1 File shows characteristics of the individual RCTs included in the seven MAs and characteristics of the individual trials are summarized in Table 1. None of the MAs included data from all the 30 RCTs.

The majority of studies included both men and women. Only two studies were of a large scale with more than 1000 participants [220,221] and most studies had a relatively short

duration. Twenty-three (77%) of the RCTs investigated effects of vitamin D supplementation as a primary endpoint (Table Gb in [S1 File](#)). Eleven trials (37%) included patients diagnosed with an infection at time of inclusion or at increased risk of acquiring infections. However, the specific infections studied varied widely between studies e.g., some investigated risk of pneumonia, upper or lower RTI, or exacerbations in patients with COPD or asthma as well as some studies included new-borns or infants where other studies focused on adults or elderly (Table Gb in [S1 File](#)). All studies investigated effects of supplementation with vitamin D3 and half of the trials (53%) administered D3 as a daily dose without concomitant calcium supplementation. Only one of the trials had low 25OHD levels (< 50 nmol/L) as inclusion criteria and mean 25OHD levels at baseline were only reported in two-thirds of the studies among which only seven trials reported mean levels below 50 nmol/L. Nine trials (30%) reported a more than 50% increase in 25OHD levels in response to treatment. A beneficial effect of vitamin D supplementation on risk of infections was found in nine (30%) of the trials, but none of the above mentioned indices were in general a characteristic of the trials showing beneficial effects of the supplementation (Table Gb in [S1 File](#)).

In *summary*, most published studies on effects of vitamin D supplementation on risk of RTI have been relatively small and of short duration without specifically addressing effects in populations with vitamin D insufficiency. Beneficial effects of vitamin D supplementation have been reported in nine of the 30 RCTs included in the 7 published MAs and three of the MAs have concluded that vitamin D supplementation may lower risk of infections. Noteworthy, the populations studied in the individual trials have varied widely from newborns to elderly as well as effects of a wide range of different types of infections have been included raising the question whether results from such different settings can be merged into MA reporting summary estimates. Nevertheless, the overall findings suggest a beneficial effect of vitamin D on respiratory tract infections.

Depression

Vitamin D may affect brain function as the VDR as well as the 1α -hydroxylase enzyme is expressed by brain tissues, suggesting that 25OHD is activated and functions within the central nervous system (CNS) [222–224]. This is further supported by findings showing effects of $1,25\text{-OH}_2\text{D}_3$ on the synthesis of nerve growth factor (NGF) [225,226], as well as the synthesis of tryptophan is transcriptionally activated by vitamin D and low 25OHD levels may accordingly cause low levels of serotonin [227].

Several cross-sectional- and cohort-studies have reported an inverse association between plasma 25OHD concentrations and depression [228–234]. In a MA on results from observational studies, low plasma 25OHD levels were associated with an increased risk of depression in cross-sectional studies ($n = 11$ studies with 43,137 participants; OR 0.96; 95% CI, 0.94, 0.99, $I^2 = 63\%$) as well as in cohort studies ($n = 5$ studies with 12,648 participants; OR 0.92; 95% CI, 0.87, 0.98, $I^2 = 50\%$) [235]. Nevertheless, other epidemiological studies have not found such associations [236–238].

We identified six SRs [239–244] among which four [239–242] provided formal MAs reporting pooled data on results from 30 RCTs on effects of vitamin D supplementation on depression (Table Ha in [S1 File](#)).

Performing a systematic literature search, Spedding et al. [239] identified 15 RCTs reporting effects of vitamin D supplementation on depression scores including mood disorders such as (seasonal) recurrent depressive disorder. Studies were subsequently grouped according to the presence of biological flaws. Biological flaws were considered if baseline 25OHD levels were not measured, if baseline levels indicated a replete vitamin D status, or if the interventions did not

cause a significant increase in 25OHD levels. Among the 15 studies identified, eight (53%) were found to have biological flaws [61,245–251], whereas seven studies (47%) were classified as being without flaws [252–258]. MAs were performed on studies with or without biological flaws. In the MA on studies without biological flaws, only two of the seven studies were included [253,257], as they used the same outcome measure in terms of Beck Depression Inventory (BDI), whereas other measures were used in the remaining five studies. Among the eight studies grouped as being with biological flaws, only two were included in MA [61,251] as they both used the 12-item Short Form Health Survey (SF-12) questionnaire, whereas other measures were used in the remaining six studies. As shown in Table Ha [S1 File](#), the authors found beneficial effects of vitamin D supplementation in the MA on studies without biological flaws, whereas no effect was present in the MA on studies classified as being with biological flaws.

In a systematic review by Li et al. [240] studies were only included if vitamin D was provided orally as mono-intervention and compared with placebo in adults considered to be at risk of depression, having depressive symptoms, or being diagnosed with depression (secondary or tertiary prevention). The protocol for the study was published prior to the results from the MA [259]. The MA included data from six RCTs (Table Hb in [S1 File](#)) among which one of the studies used calcitriol as treatment [250]. For some of the included studies, only subgroups of the randomized population were considered for data-analyses. For example, in the study by Sanders et al. [61], only 137 of the 2258 randomized women were included, as only this subgroup provided concurrent information on changes in 25OHD levels and changes in scores as assessed by the WHI-5 questionnaire. Overall, the meta-analysis by Li et al. [240] showed no effects of vitamin D supplementation on studied indices (Table Ha in [S1 File](#)). In subgroup analysis stratified by vitamin D dosages, sex, study location, and different study populations, no effects of vitamin D were found. In a post hoc analysis stratified by vitamin D status at baseline (sufficient vs deficient), no significant differences between groups were observed [240]. Similarly, Shaffer et al [241] and Gowda et al [242] found no significant differences when comparing studies with mean baseline 25OHD levels below or above 50 nmol/L. For most of the analyses performed, a substantial unexplained heterogeneity was present and the quality of evidence obtained from the included trials was graded as low by the authors [240]. Similarly, no overall beneficial effects of vitamin D supplementation were found in the MAs by Shaffer et al (221) and Gowda et al [242] and a substantial and unexplained heterogeneity was also found in most analyses (Table Ha in [S1 File](#)).

Table Hb in [S1 File](#) shows summary characteristics of the 12 RCTs included in the four MAs. The trials have been published between 2003 and 2013. In four (33%) of the trials, depression was considered as a primary end-point. Four of the RCTs included only women (none of the studies included only men). Three studies included solely patients with a diagnosis of depression; none of them on treatment with antidepressant at time of inclusion. One study included only elderly women with known seasonal affective disorders (treatment status unknown). The remaining studies included community-dwelling men and women among which two of the studies excluded participants on treatment with antidepressants. In three studies, participants were only included if they had 25OHD levels below 40 or 55 nmol/L or between 25–75 nmol/L. In 10 of the studies, vitamin D supplementation was given orally as vitamin D3 tablets/capsules (9 studies) or as fortified cheese (1 study). One study used intramuscular D3-injections and one study tested calcitriol. Vitamin D was given daily (7 studies), weekly (3 studies), yearly (1 study), or as a single dose (1 study). Time from initiation of treatment to end of follow-up varied from six weeks to five years. Effects were assessed by Beck Depression Inventory (BDI) in five studies, by the Geriatric Depression Scale (GDS) in two studies, and by the SF-12 questionnaire in two studies. One study used the Burnam 8-item scale for depressive disorders whereas another study used a questionnaire designed for patients

with fibromyalgia which included depression as a domain. Only three of the individual RCTs showed beneficial effects [254,257,260] among which effects of the intervention was considered as a primary endpoint in two of the trials [257,260]. In one study, a per-protocol analysis showed a decrease in depressive symptoms compared with placebo in the cognitive-affective domain (subscale 1–13) of BDI [253]. In a sub-analysis from the WHI study, the Burnam-score was worsened by vitamin D compared with placebo (0.009; 95% CI, 0.002, 0.017) in the group of women without evidence of prior depression [246]. No major effects were shown in sub-analyses in any of the other studies.

In summary, only one of four MAs has suggested a beneficial effect of vitamin D supplementation on depression. This MA included only few of the published studies, whereas the three MAs showing no effects of vitamin D supplementation allowed for inclusion of more of the published RCTs. However, the methods used to assess effects in the various RCTs varied widely and only few ($N = 5$) studies reported an increase in 25OHD levels above 50% in response to the intervention. Moreover, most of the studies ($N = 11$) did not require their participants to have vitamin D insufficiency ($25\text{OHD} < 50 \text{ nmol/L}$) at inclusion and only five studies reported mean baseline 25OHD levels below 50 nmol/L . It is nevertheless noteworthy that both the MA by Li et al. [240] and the MA by Shaffer et al. [241] suggested beneficial effects of vitamin D supplementation among those with a replete vitamin D status, but not in subjects with low vitamin D levels which does not support findings from observational studies of a major role of vitamin D in the pathogenesis of depression.

Mortality

Observational studies have shown an inverse association between 25OHD levels and mortality, including death from CVD, cancer, and non-vascular, non-cancer causes [194,261–266]. The mechanism by which supplementation with vitamin D may reduce mortality has not been fully clarified, but it has been suggested that the reduced risk of death may be due to the possible pleiotropic effect that involved the musculo-skeletal- as well as several extraskeletal-systems, including anti-inflammatory and immune modulating effects [267,268].

We identified 12 SRs with MAs on mortality in response to supplementation with vitamin D. Eight of the MAs showed a significantly reduced mortality in response to supplementation (Table Ia in [S1 File](#)). In most of the MAs, stratification by type of calciferol showed a significantly reduced mortality in response to treatment with vitamin D₃, whereas no beneficial effects were found in response to treatment with vitamin D₂ [190,263,269–271]. Discrepant results have been reported on whether mortality is reduced in response to treatment with vitamin D alone [263,269] or only if vitamin D is combined with calcium supplements [190,270–272]. In two MAs, effects of the intervention was significant in summary estimates on trials with low baseline vitamin D status [190,271], but a clear dose-response relationship has not been documented [49,269,271,272].

The 12 MAs included data from a total of 59 RCTs. Table Ib in [S1 File](#) shows characteristics of the individual RCTs included in the 12 MAs and characteristics of the individual trials are summarized in [Table 1](#). None of the RCTs had mortality as a primary endpoint and none of them showed a significantly reduced mortality in response to treatment. Actually, two small trials showed an increased mortality in response to the supplementation [273,274]. In the study by Latham et al. [273], a single high dose (300,000 IU) of vitamin D₃ increased mortality during the following six months compared with placebo in a group of 243 frail elderly people. Similarly, a high dose of D₂ (100,000 IU every 3rd month) increased mortality compared with no treatment during a 10 months study period in a group of 3,717 nursing home residents [274]. On the other hand, none of the studies with daily administration of vitamin D supplements has

shown increased mortality in response to supplementation, including a recently published trial on three-years of daily supplementation with 4000 IU D3 or placebo to 400 patients with heart failure [275]. Most studies have been relatively small with less than 1000 randomized participants and have investigated effects of a daily dose of vitamin D3 with calcium being co-administered in approximately half of the studies. Only few of the studies ($N = 5$) had low 25OHD levels as a criterion for inclusion. Seventeen of the 59 studies reported an increase in 25OHD levels of more than 50% in response to the intervention. Mean 25OHD levels were below 50 nmol/L in approximately half of the studies. Several of the MAs compared effects between studies with mean baseline levels below or above 50 nmol/L showing no significant interactions [49,270,276,277]. However, stratified analyses showed a significantly decreased mortality when pooling results from studies with mean 25OHD levels below 50 nmol/L, but not when combining results from studies with mean levels above 50 nmol/L [190,270,276].

In summary, supplementation with vitamin D seems to be causally related to a reduce all-cause mortality, which is in accordance with the findings from observational studies. Moreover, as reviewed in the section on malignant diseases, MAs on cause specific mortality have shown a reduced mortality due to malignant diseases [184,186,190]. Only vitamin D3 has been shown to reduce mortality, and some MAs have suggested that the effect only is present if calcium is co-administered, whereas other MAs have shown an effect of vitamin D3 alone. The lack of a clear dose-response relationship may be attributable to characteristics of the RCTs included in the MAs, as most of the trials have investigated effects of low doses (Table Ib in S1 File) which may limit the statistical power to show dose-effect relationships. Furthermore, as recently shown in a simulation analysis, based on findings from a large cohort study, the expected impact on mortality of vitamin D supplementation is presumably much higher if targeted to individuals with low 25OHD levels [278].

Discussion

Overall, 16 of the 54 MAs suggested beneficial effects of vitamin D supplementation on different extra-skeletal outcomes among which eight of 12 MAs (66%) reported a decreased mortality. Beneficial effects were also suggested by MAs on blood pressure (2 of 9 [22%] MAs), birth weight (2 of 6 [33%] MAs), RTIs (3 of 7 [43%] MAs), and depression (1 of 4 [25%] MAs). No beneficial effects were reported in any of the MAs on CVD, T2D, body weight, or malignant diseases.

For all studied outcomes, only one-fourth of the individual RCTs included in the MAs had assessed effects studied as a primary endpoint. None of the trials included in the 12 MAs on mortality had mortality as a designated primary outcome. Most studies have been performed only in women or in a mixed gender population, whereas only very few studies included only men. The sex distribution is probably because many of the included studies have investigated skeletal effects as primary outcomes. As osteoporosis and fractures are more common in women than in men, these studies have preferentially included women in order to achieve effects in a population at high risk. However, although many of the trials have assessed effects of vitamin D supplementation on skeletal outcomes, only a minority of the studies have actually investigated effects in populations with low 25OHD levels. Plasma 25OHD levels below 50 nmol/L were only inclusion criteria in one-fourth of the analyses.

Moreover, mean 25OHD levels at baseline below 50 nmol/L has only been measured in less than half of the studies, indicating that the populations studied did not, on average, suffer from vitamin D insufficiency and the duration of studies has in many studies been relatively short. The WHI study is the trial with the longest time of intervention (7 years) and the most participants included [279].

The vast majority of observational studies have reported low 25OHD levels to be associated with an increased risk of adverse health outcomes, but caution is needed in interpreting observational data. Although most studies have adjusted for differences between groups, residual confounding can never be excluded in observational studies. Effects may be due to lifestyle factors, a “healthy user” bias or other differences between groups, which has not been fully accounted for in adjusted analyses. This may result in reverse causation, in which vitamin D status is more a marker for an underlying condition/disease than causally related to the disease investigated. Accordingly, RCTs are needed to determine whether a causal link is present. Following the publications of a large number of observational studies showing adverse health outcomes of low 25OHD levels, the requests of data from RCTs have increased. For each of the outcomes we studied, a variable number of RCTs have been published and most of them have failed to document a beneficial effect as shown in observational studies. Accordingly, it may seem questionable whether the findings from observational studies actually reflect a beneficial effect of vitamin D by itself. Due to such findings, a recent large scale review by Autier et al [19] concluded that the inverse association between 25OHD levels and various health outcomes, could be the result of disease process causing low 25OHD levels rather than low 25OHD levels causing the disease i.e., low 25OHD levels are a marker of ill health.

In our review, we aimed to summarize characteristics of the published RCTs on effects of vitamin D supplementation. Although, RCTs are considered as the highest level of evidence, and especially if results from RCTs are summarized in MA, the degree of confidence on the findings from the RCTs do, however, depend on how the studies were performed and whether they actually had a design and statistical power to detect possible effects. Our review highlights that most of the available trials were not designed to study non-skeletal outcomes of vitamin D supplementation. For most of the selected outcomes reviewed in this paper, the RCTs included in MAs did not have the disease in question as primary outcome. For several of the diseases studied, some of the outcomes were assessed as adverse event reports and many of the studies had a questionable statistical power to detect effects such as incident CVDs or cancers. The lack of trials assessing effects of intervention on specific health outcomes as a primary end-point does, however, not provide a complete answer to the discrepancy between findings from observational and randomized trials. For example, in analyses on mortality, none of the individual RCTs showed beneficial effects and none of the trials were designed to assess mortality. However, several of the pooled risk estimates in MAs did show a significantly reduced risk of death in response to treatment. Notably, the MAs on mortality have included substantially more studies than most of the MAs on other studied outcomes and mortality may be assessed in a more valid manner than other “adverse effects” observed during a trial. If vitamin D supplementation affects studied outcomes the sample size may have been too small to show effects, which may have been further hampered by a relatively short duration of treatment. CVD, obesity, T2D, and cancers develop over a long time, and the duration of the trials available may not be sufficiently long to affect such disease processes. Historically, it has been shown multiple times that RCTs are difficult to perform in terms of testing the right dose for an appropriate time-period in a suitable population of study subjects and that null-findings do not necessary disprove important effects [17,280,281]. Interestingly, a beneficial effect of vitamin D supplementation was shown in several of the trials on RTIs, which are outcomes that seems more likely to be affected by a relatively short duration of treatment compared with for example CVD or cancer. The most noticeable difference between the observational and randomized trials is, however, that only few of the RCTs included participants with vitamin D insufficiency. Many studies did not report mean 25OHD levels, but among studies reporting these values, mean levels were below 50 nmol/L in less than half of the studies and the intervention did not result in a marked increase in 25OHD levels in several of the trials. Only a few of the included

MA's investigated whether findings differed according to baseline vitamin D status showing no significant interaction between results from studies with mean 25OHD levels below vs. above 50 nmol/L or according to whether supplementation resulted in increased 25OHD levels on cardiovascular outcomes [49], blood pressure [81], body weight [137], malignant diseases [184], RTI [212,218] or mortality [49,270,276,277]. A significant interaction term ($P_i = 0.006$) was only shown for RTI in the recently published MA by Martineau et al [22] showing a larger decrease in risk of RTI if baseline 25OHD levels are below as compared with above 25 nmol/L. Of importance, a mean level below 50 nmol/L implies that only approximately half of the population had levels below 50 nmol/L, which may have blunted a potential effect in subjects with low levels. Accordingly, it is questionable whether available trials as well as MA's performed by combining trial results in reality have tested the hypothesis raised by observational studies on adverse health effects of low 25OHD levels. A beneficial effect of vitamin D supplementation is most likely difficult to demonstrate if studies are performed in populations with adequate levels. Moreover, factors such as compliance, sources of vitamin D, etc. have to be considered when evaluating findings from RCTs as well as in the design of further studies [194,282]. We choose to classify studies according to a cut-off plasma level of 25OHD equal to 50 nmol/L, as consensus exist on considering this threshold limit as a state of inadequacy [283], although some have suggested that a sufficient vitamin D status requires levels above 80 nmol/L [284]. Importantly, the optimal 25OHD level for non-skeletal health outcomes have not yet been clarified and the available RCTs do not allow for such definitions [27]. Lack of effects may be attributable to use of too low doses of vitamin D to achieve a sufficient response. In terms of this, it may be of relevance in future studies also to consider the relationship between vitamin D dose, baseline and achieved 25OHD concentrations as well as the fact that the relationship between vitamin D dose and 25OHD concentration is nonlinear and can vary due to personal factors [194].

A further limitation to some of the RCTs might be that some of the studies have used intermittent treatment with high doses of vitamin D. Although such dosing regimes results in high levels of 25OHD, levels of cholecalciferol are negligible for most of the time due to the rapid 25-hydroxylation of vitamin D3 into 25OHD. Vitamin D3 acts as a substrate in many tissues thereby being of importance to the vitamin D endocrine/autocrine system. Accordingly, it is likely that vitamin D3 should be available on a daily basis through supplementation or endogenous synthesis in order to achieve effects of vitamin D3 [285]. It may also be questioned whether effects of supplementation with vitamin D are equal to endogenous synthesis. In recent studies, novel secosteroids with potential actions similar to 25OHD have been shown to be synthesized in vivo in human epidermis and in pig adrenal glands [286]. These compounds may function as substrates for the 1α -hydroxylase and thereby potentially act in a manner similar to activated vitamin D. Further studies are needed to determine whether this is of importance to the effects of vitamin D and if it makes a difference whether vitamin D is synthesized endogenously or provided as in terms of supplementation with cholecalciferol. Additionally, UV irradiation through sun-exposure may also cause liberation of nitric oxide from subcutaneous nitrogen stores thereby affecting non-skeletal outcomes such as blood pressure beyond potential effects of vitamin D synthesis [287–289]. Finally, it should also be noted that our assessment of findings on non-skeletal outcomes is not exhaustive, as effects of vitamin D supplementation also have been studied on other outcomes such as dental caries [290].

Directions for further investigations

As highlighted by our review, the quality of data from available RCTs is of limited value in terms of assessing non-skeletal effects of vitamin D supplementation. Further MA's performed

on these data are therefore not to be considered as a priority. MA does not compensate for shortcomings in the original studies. Further RCTs designed to assess effects of vitamin D supplementation on specific outcomes within a population at risk are warranted. A number of large-scale trials are currently being performed. These studies aim at assessing non-skeletal outcomes of vitamin D supplementation and first results are expected within the next year [291,292]. Although these studies plan to include from 6,000 to 25,874 participants, and thereby potentially provide a substantial statistical power to detect potential effects, most of these studies are not targeted towards subjects with vitamin D insufficiency [293]. Accordingly, they do not assess effects of the intervention in a population at specific risk where potential effects of improving vitamin D status may be blunted by inclusion of individuals with a replete vitamin D status.

Assessing effects of vitamin D supplementation in randomized trials is complicated by a number of factors [294]. Even if a large-scale study was performed in a population with vitamin D insufficiency at baseline, changes in vitamin D status may occur in the control group during the course of the trial due to altered dietary habits and/or sun-exposure, including seasonal-variations [295–297]. Moreover, vitamin D supplements are readily available and controls may start using vitamin supplements. Finally, assessment of effects in diseases which develop over a long time span such as CVD or obesity may be difficult during the course of a trial which most often only runs for a few years. Effects may also depend on the age of studied subjects and risk for developing such chronic diseases may be grounded in early life [298,299]. If so, a replete vitamin D status throughout life or at certain ages may be of importance. Although RCTs are considered to provide the highest degree of evidence on causal relationships, this methodology may not be appropriate to rely on, if the effects of vitamin D are of importance at a certain period of life or during a long time span. Thus, the importance of well-designed longitudinal studies should not be entirely rejected. Development of new methods or reliance on the Bradford Hill criteria may be necessary to refine our understanding of vitamin D [300]. A major limitation to the interpretation of prior longitudinal studies is lack of standardization of 25OHD measurements [301]. It has been documented that use of different methods for measuring 25OHD levels may cause huge variations in levels measured and thereby affect the classification of vitamin D status [302–305]. Further observational studies should therefore aim at using standardized methods for vitamin D measurements in order to allow for comparisons across studies and time periods. Such observational studies may also help to provide guidance on threshold values of 25OHD levels of importance to non-skeletal outcomes.

Conclusions

Observational studies have suggested an inverse association between vitamin D status and a number of diseases. Results from RCTs and MAs of RCTs do, however, only provide limited support for such effects, as most studies have failed to document significant effects. Nevertheless, several MAs have suggested a reduced mortality in response to vitamin D supplementation, as well as three of seven MAs showed a beneficial effect on RTIs, including a recently published large individual patient data analysis [22]. Only sparse evidence are available for a beneficial effect of supplementation on other non-skeletal outcomes such as blood pressure, depression, and increased birth weight. No MAs based on findings from RCTs have so far provided support for a beneficial effect of supplementation on risk of CVD, T2D, body weight, or malignant diseases. More than half of the available trials have been performed in individuals without vitamin D insufficiency and the intervention has not resulted in an adequate increase in 25OHD levels in many of the trials. Furthermore, the sample size in most RCTs

was relatively small and the trials had a short duration of follow-up. In accordance with the null findings in most RCTs, most meta-analyses have not shown effects of vitamin D supplementation on non-skeletal outcomes. Importantly, as evaluated by the AMSTAR score, the quality of published MAs has largely been fair to good. The null findings of MAs are therefore not attributable to an inappropriate methodology when combining data from RCTs. MAs cannot be expected to proof potential effects of supplementation with vitamin D, if the trials forming the basis for the MAs have not been performed in populations with low 25OHD levels. Overall, a definite causal link between vitamin D insufficiency and non-skeletal diseases has not been proven, but the RCTs performed so far cannot be considered to have tested the hypothesis raised by observational studies on adverse health outcomes of low vitamin D levels. As a “healthy user” bias and reverse causation cannot be excluded in observational studies, further RCTs designed to test the hypothesis of a beneficial effect of optimizing vitamin D status in individuals with an impaired vitamin D status are warranted, as well as long-term cohort studies using standardized methods for serial measurement of 25OHD levels.

Supporting information

S1 File. Supplementary tables.

(DOCX)

S2 File. PRISMA checklist.

(DOC)

Author Contributions

Conceptualization: Lars Rejnmark, Lise Sofie Bislev, Kevin D. Cashman, Gudny Eiríksdóttir, Martin Gaksch, Martin Gröbler, Guri Grimnes, Vilmondur Gudnason, Paul Lips, Stefan Pilz, Natasja M. van Schoor, Mairead Kiely, Rolf Jorde.

Data curation: Lars Rejnmark, Lise Sofie Bislev.

Formal analysis: Lars Rejnmark, Lise Sofie Bislev.

Funding acquisition: Kevin D. Cashman, Mairead Kiely.

Investigation: Lars Rejnmark, Lise Sofie Bislev, Kevin D. Cashman, Gudny Eiríksdóttir, Martin Gaksch, Martin Gröbler, Guri Grimnes, Vilmondur Gudnason, Paul Lips, Stefan Pilz, Natasja M. van Schoor, Mairead Kiely, Rolf Jorde.

Methodology: Lars Rejnmark, Lise Sofie Bislev, Kevin D. Cashman, Gudny Eiríksdóttir, Martin Gaksch, Martin Gröbler, Guri Grimnes, Vilmondur Gudnason, Paul Lips, Stefan Pilz, Natasja M. van Schoor, Mairead Kiely, Rolf Jorde.

Project administration: Lars Rejnmark, Kevin D. Cashman, Mairead Kiely, Rolf Jorde.

Supervision: Lars Rejnmark, Kevin D. Cashman, Gudny Eiríksdóttir, Martin Gaksch, Martin Gröbler, Guri Grimnes, Vilmondur Gudnason, Paul Lips, Stefan Pilz, Natasja M. van Schoor, Mairead Kiely, Rolf Jorde.

Writing – original draft: Lars Rejnmark, Lise Sofie Bislev.

Writing – review & editing: Kevin D. Cashman, Gudny Eiríksdóttir, Martin Gaksch, Martin Gröbler, Guri Grimnes, Vilmondur Gudnason, Paul Lips, Stefan Pilz, Natasja M. van Schoor, Mairead Kiely, Rolf Jorde.

References

1. Adams JS, Hewison M. Extrarenal expression of the 25-hydroxyvitamin D-1-hydroxylase. *Archives of Biochemistry and Biophysics* 2012; 523: 95–102. <https://doi.org/10.1016/j.abb.2012.02.016> PMID: 22446158
2. DeLuca HF. TRIENNIAL GROWTH SYMPOSIUM- Vitamin D: Bones and beyond1,2. *J Anim Sci* 2014; 92: 917–929. <https://doi.org/10.2527/jas.2013-7237> PMID: 24363329
3. Jones G, Strugnell SA, DeLuca HF. Current Understanding of the Molecular Actions of Vitamin D. *Physiol Rev* 1998; 78: 1193–1231. PMID: 9790574
4. van der Wielen RPJ, de Groot LCPG, van Staveren WA, Löwik MRH, van den Berg H, Haller J et al. Serum vitamin D concentrations among elderly people in Europe. *The Lancet* 1995; 346: 207–210.
5. van Schoor NM, Lips P. Worldwide vitamin D status. *Best Practice & Research Clinical Endocrinology & Metabolism* 2011; 25: 671–680.
6. Lips P. Vitamin D status and nutrition in Europe and Asia. *The Journal of Steroid Biochemistry and Molecular Biology* 2007; 103: 620–625. <https://doi.org/10.1016/j.jsbmb.2006.12.076> PMID: 17287117
7. Bruyère O, Slomian J, Beaudart C, Buckinx F, Cavalier E, Gillain S et al. Prevalence of vitamin D inadequacy in European women aged over 80 years. 2014; 59: 78–82. <https://doi.org/10.1016/j.archger.2014.03.010> PMID: 24784761
8. Bruyère O, Malaise O, Neuprez A, Collette J, Reginster JY. Prevalence of vitamin D inadequacy in European postmenopausal women. 2007; 23: 1939–1944. <https://doi.org/10.1185/030079907X219562> PMID: 17631697
9. Mithal A, Wahl DA, Bonjour JP, Burckhardt P, wson-Hughes B, Eisman JA et al. Global vitamin D status and determinants of hypovitaminosis D. *Osteoporos Int* 2009; 20: 1807–1820. <https://doi.org/10.1007/s00198-009-0954-6> PMID: 19543765
10. Pourshahidi LK. Vitamin D and obesity: current perspectives and future directions. *Proceedings of the Nutrition Society* 2014; FirstView: 1–10.
11. Antico A, Tampoia M, Tozzoli R, Bizzaro N. Can supplementation with vitamin D reduce the risk or modify the course of autoimmune diseases? A systematic review of the literature. *Autoimmunity Reviews* 2012; 12: 127–136. <https://doi.org/10.1016/j.autrev.2012.07.007> PMID: 22776787
12. Seida JC, Mitri J, Colmers IN, Majumdar SR, Davidson MB, Edwards AL et al. Effect of Vitamin D Supplementation on Improving Glucose Homeostasis and Preventing Diabetes: A Systematic Review and Meta-Analysis. *J Clin Endocrinol Metab* 2014; 99: 3551–3560. <https://doi.org/10.1210/jc.2014-2136> PMID: 25062463
13. Chowdhury R, Stevens S, Ward H, Chowdhury S, Sajjad A, Franco O. Circulating vitamin D, calcium and risk of cerebrovascular disease: a systematic review and meta-analysis. *Eur J Epidemiol* 2012; 27: 581–591. <https://doi.org/10.1007/s10654-012-9729-z> PMID: 22961293
14. Souberbielle JC, Body JJ, Lappe JM, Plebani M, Shoenfeld Y, Wang TJ et al. Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: Recommendations for clinical practice. *Autoimmunity Reviews* 2010; 9: 709–715. <https://doi.org/10.1016/j.autrev.2010.06.009> PMID: 20601202
15. Muscogiuri G, Mitri J, Mathieu C, Badenhop K, Tamer G, Orio F et al. MECHANISMS IN ENDOCRINOLOGY: Vitamin D as a potential contributor in endocrine health and disease. *Eur J Endocrinol* 2014; 171: R101–R110. <https://doi.org/10.1530/EJE-14-0158> PMID: 24872497
16. Cashman KD, Dowling KG, Skrabáňková Z, Gonzalez-Gross M, Valtueña J, De Henauw S et al. Vitamin D deficiency in Europe: pandemic? *Am J Clin Nutr* 2016; 103: 1033–1044. <https://doi.org/10.3945/ajcn.115.120873> PMID: 26864360
17. Sackett DL, Rosenberg WMC, Gray JAM, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn't. *BMJ* 1996; 312: 71–72. PMID: 8555924
18. Theodoratou E, Tzoulaki I, Zgaga L, John PA. Vitamin D and multiple health outcomes: umbrella review of systematic reviews and meta-analyses of observational studies and randomised trials. *BMJ* 2014; 348.
19. Autier P, Boniol M, Pizot C, Mullie P. Vitamin D status and ill health: a systematic review. *The Lancet Diabetes & Endocrinology* 2014; 2: 76–89.
20. Calton EK, Keane KN, Newsholme P, Zhao Y, Soares MJ. The impact of cholecalciferol supplementation on the systemic inflammatory profile: a systematic review and meta-analysis of high-quality randomized controlled trials. *Eur J Clin Nutr* 2017.
21. Mahomed K, Gulmezoglu AM. Vitamin D supplementation in pregnancy. *Cochrane Database Syst Rev* 2000; CD000228. <https://doi.org/10.1002/14651858.CD000228> PMID: 10796185

22. Martineau AR, Jolliffe DA, Hooper RL, Greenberg L, Aloia JF, Bergman P et al. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. *BMJ* 2017; 356.
23. Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, Hamel C et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. *BMC Medical Research Methodology* 2007; 7: 10. <https://doi.org/10.1186/1471-2288-7-10> PMID: 17302989
24. Shea BJ, Bouter LM, Peterson J, Boers M, Andersson N, Ortiz Z et al. External Validation of a Measurement Tool to Assess Systematic Reviews (AMSTAR). *PLoS ONE* 2007; 2: e1350. <https://doi.org/10.1371/journal.pone.0001350> PMID: 18159233
25. Kendrick J, Targher G, Smits G, Chonchol M. 25-Hydroxyvitamin D deficiency is independently associated with cardiovascular disease in the Third National Health and Nutrition Examination Survey. *Atherosclerosis* 2009; 205: 255–260. <https://doi.org/10.1016/j.atherosclerosis.2008.10.033> PMID: 19091317
26. Giovannucci E, Liu Y, Hollis BW, Rimm EB. 25-Hydroxyvitamin D and Risk of Myocardial Infarction in Men: A Prospective Study. *Arch Intern Med* 2008; 168: 1174–1180. <https://doi.org/10.1001/archinte.168.11.1174> PMID: 18541825
27. Cashman KD. A review of vitamin D status and CVD. *Proceedings of the Nutrition Society* 2014; 73: 65–72. <https://doi.org/10.1017/S0029665113003595> PMID: 24103845
28. Targher G, Bertolini L, Padovani R, Zenari L, Scala L, Cigolini M et al. Serum 25-hydroxyvitamin D3 concentrations and carotid artery intima-media thickness among type 2 diabetic patients. *Clin Endocrinol (Oxf)* 2006; 65: 593–597.
29. Melamed ML, Muntner P, Michos ED, Uribarri J, Weber C, Sharma J et al. Serum 25-Hydroxyvitamin D Levels and the Prevalence of Peripheral Arterial Disease: Results from NHANES 2001 to 2004. *Arterioscler Thromb Vasc Biol* 2008; 28: 1179–1185. <https://doi.org/10.1161/ATVBAHA.108.165886> PMID: 18417640
30. Dobnig H, Pilz S, Scharnagl H, Renner W, Seelhorst U, Wellnitz B et al. Independent Association of Low Serum 25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D Levels With All-Cause and Cardiovascular Mortality. *Arch Intern Med* 2008; 168: 1340–1349. <https://doi.org/10.1001/archinte.168.12.1340> PMID: 18574092
31. Pilz S, Marz W, Wellnitz B, Seelhorst U, Fahrleitner-Pammer A, Dimai HP et al. Association of Vitamin D Deficiency with Heart Failure and Sudden Cardiac Death in a Large Cross-Sectional Study of Patients Referred for Coronary Angiography. *Journal of Clinical Endocrinology Metabolism* 2008; 93: 3927–3935. <https://doi.org/10.1210/jc.2008-0784> PMID: 18682515
32. Sokol SI, Tsang P, Aggarwal V, Melamed ML, Srinivas VS. Vitamin D status and risk of cardiovascular events: lessons learned via systematic review and meta-analysis. *Cardiol Rev* 2011; 19: 192–201. <https://doi.org/10.1097/CRD.0b013e31821da9a5> PMID: 21646873
33. Wang L, Song Y, Manson JE, Pilz S, März W, Michaëlsson K et al. Circulating 25-Hydroxy-Vitamin D and Risk of Cardiovascular Disease: A Meta-Analysis of Prospective Studies. *Circulation: Cardiovascular Quality and Outcomes* 2012; 5: 819–829.
34. Merke J, Hofmann W, Goldschmidt D, Ritz E. Demonstration of 1,25(OH)₂ vitamin D₃ receptors and actions in vascular smooth muscle cells in vitro. *Calcif Tissue Int* 1987; 41: 112–114. PMID: 2820558
35. Merke J, Milde P, Lewicka S, Hugel U, Klaus G, Mangelsdorf DJ et al. Identification and regulation of 1,25-dihydroxyvitamin D₃ receptor activity and biosynthesis of 1,25-dihydroxyvitamin D₃. Studies in cultured bovine aortic endothelial cells and human dermal capillaries. *J Clin Invest* 1989; 83: 1903–1915. <https://doi.org/10.1172/JCI114097> PMID: 2542376
36. Schnatz PF, Manson JE. Vitamin D and Cardiovascular Disease: An Appraisal of the Evidence. *Clin Chem* 2014; 60: 600–609. <https://doi.org/10.1373/clinchem.2013.211037> PMID: 24193116
37. Wu-Wong JR, Nakane M, Ma J, Ruan X, Kroeger PE. VDR-mediated gene expression patterns in resting human coronary artery smooth muscle cells. *J Cell Biochem* 2007; 100: 1395–1405. <https://doi.org/10.1002/jcb.21133> PMID: 17115413
38. Wu-Wong JR, Nakane M, Ma J. Vitamin D analogs modulate the expression of plasminogen activator inhibitor-1, thrombospondin-1 and thrombomodulin in human aortic smooth muscle cells. *J Vasc Res* 2007; 44: 11–18. <https://doi.org/10.1159/000097812> PMID: 17159355
39. Mangge H, Becker K, Fuchs D, Gostner JM. Antioxidants, inflammation and cardiovascular disease. *World J Cardiol* 2014; 6: 462–477. <https://doi.org/10.4330/wjc.v6.i6.462> PMID: 24976919
40. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. *N Engl J Med* 2005; 352: 1685–1695. <https://doi.org/10.1056/NEJMra043430> PMID: 15843671
41. Schnatz PF, Vila-Wright S, Jiang X, Register TC, Kaplan JR, Clarkson TB et al. The association between plasma 25-hydroxyvitamin D₃ concentrations, C-reactive protein levels, and coronary artery

- atherosclerosis in postmenopausal monkeys. *Menopause* 2012; 19: 1074–1080. <https://doi.org/10.1097/gme.0b013e31825499f0> PMID: 22713861
42. DeLuca HF, Cantorna MT. Vitamin D: its role and uses in immunology. *FASEB J* 2001; 15: 2579–2585. <https://doi.org/10.1096/fj.01-0433rev> PMID: 11726533
43. Maruotti N, Cantatore FP. Vitamin D and the immune system. *J Rheumatol* 2010; 37: 491–495. <https://doi.org/10.3899/jrheum.090797> PMID: 20080911
44. Upala S, Sanguankee A, Congrete S, Jaruvongvanich V. Effect of cholecalciferol supplementation on arterial stiffness: a systematic review and meta-analysis. *Scandinavian Cardiovascular Journal* 2016; 50: 230–235. <https://doi.org/10.3109/14017431.2016.1173226> PMID: 27101968
45. Jiang WL, Gu HB, Zhang YF, Xia QQ, Qi J, Chen JC. Vitamin D Supplementation in the Treatment of Chronic Heart Failure: A Meta-analysis of Randomized Controlled Trials. *Clin Cardiol* 2016; 39: 56–61. <https://doi.org/10.1002/clc.22473> PMID: 26415519
46. Pittas AG, Chung M, Trikalinos T, Mitri J, Brendel M, Patel K et al. Systematic Review: Vitamin D and Cardiometabolic Outcomes. *Ann Intern Med* 2010; 152: 307–314. <https://doi.org/10.7326/0003-4819-152-5-201003020-00009> PMID: 20194237
47. Chung M, Tang AM, Fu Z, Wang D, Newberry S. Calcium intake and cardiovascular disease risk: An updated systematic review and meta-analysis. *Ann Intern Med* 2016.
48. Wang L, Manson JE, Song Y, Sesso HD. Systematic review: Vitamin D and calcium supplementation in prevention of cardiovascular events. *Ann Intern Med* 2010; 152: 315–323. <https://doi.org/10.7326/0003-4819-152-5-201003020-00010> PMID: 20194238
49. Elamin MB, bu Elnour NO, Elamin KB, Fatourehchi MM, Alkatib AA, Almandoz JP et al. Vitamin D and cardiovascular outcomes: a systematic review and meta-analysis. *J Clin Endocrinol Metab* 2011; 96: 1931–1942. <https://doi.org/10.1210/jc.2011-0398> PMID: 21677037
50. Myung S-K, Ju W, Cho B, Oh S-W, Park SM, Koo B-K et al. Efficacy of vitamin and antioxidant supplements in prevention of cardiovascular disease: systematic review and meta-analysis of randomised controlled trials. *BMJ* 2013; 346.
51. Mao PJ, Zhang C, Tang L, Xian YQ, Li YS, Wang WD et al. Effect of calcium or vitamin D supplementation on vascular outcomes: A meta-analysis of randomized controlled trials. *Int J Cardiol* 2013; 169: 106–111. <https://doi.org/10.1016/j.ijcard.2013.08.055> PMID: 24035175
52. Fortmann SP, Burda BU, Senger CA, Lin JS, Whitlock EP. Vitamin and Mineral Supplements in the Primary Prevention of Cardiovascular Disease and Cancer: An Updated Systematic Evidence Review for the U.S. Preventive Services Task Force. *Ann Intern Med* 2013; 159: 824–834. <https://doi.org/10.7326/0003-4819-159-12-201312170-00729> PMID: 24217421
53. Ford JA, MacLennan GS, Avenell A, Bolland M, Grey A, Witham M et al. Cardiovascular disease and vitamin D supplementation: trial analysis, systematic review, and meta-analysis. *Am J Clin Nutr* 2014; 100: 746–755. <https://doi.org/10.3945/ajcn.113.082602> PMID: 25057156
54. Bolland MJ, Grey A, Gamble GD, Reid IR. The effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes: a trial sequential meta-analysis. *Lancet Diabetes Endocrinol* 2014; 2: 307–320. [https://doi.org/10.1016/S2213-8587\(13\)70212-2](https://doi.org/10.1016/S2213-8587(13)70212-2) PMID: 24703049
55. Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. *BMJ* 2003; 326: 469. <https://doi.org/10.1136/bmj.326.7387.469> PMID: 12609940
56. Witham MD, Price RG, Struthers AD. Cholecalciferol treatment to reduce blood pressure in older patients with isolated systolic hypertension: The VitDISH randomized controlled trial. *JAMA Internal Medicine* 2013; 173: 1672–1679. <https://doi.org/10.1001/jamainternmed.2013.9043> PMID: 23939263
57. Brazier M, Grados F, Kamel S, Mathieu M, Morel A, Maamer M et al. Clinical and laboratory safety of one year's use of a combination calcium + vitamin D tablet in ambulatory elderly women with vitamin D insufficiency: Results of a multicenter, randomized, double-blind, placebo-controlled study. *Clin Ther* 2005; 27: 1885–1893. <https://doi.org/10.1016/j.clinthera.2005.12.010> PMID: 16507374
58. Gallagher JC, Sai A, Templin II, Smith L. Dose Response to Vitamin D Supplementation in Postmenopausal Women—A Randomized Trial. *Ann Intern Med* 2012; 156: 425–437. <https://doi.org/10.7326/0003-4819-156-6-201203200-00005> PMID: 22431675
59. Grant AM, Avenell A, Campbell MK, McDonald AM, MacLennan GS, McPherson GC et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial. *Lancet* 2005; 365: 1621–1628. [https://doi.org/10.1016/S0140-6736\(05\)63013-9](https://doi.org/10.1016/S0140-6736(05)63013-9) PMID: 15885294
60. Prince RL, Austin N, Devine A, Dick IM, Bruce D, Zhu K. Effects of Ergocalciferol Added to Calcium on the Risk of Falls in Elderly High-Risk Women. *Arch Intern Med* 2008; 168: 103–108. <https://doi.org/10.1001/archinternmed.2007.31> PMID: 18195202

61. Sanders KM, Stuart AL, Williamson EJ, Jacka FN, Dodd S, Nicholson G et al. Annual high-dose vitamin D3 and mental well-being: randomised controlled trial. *Br J Psychiatry* 2011; 198: 357–364. <https://doi.org/10.1192/bjp.bp.110.087544> PMID: 21525520
62. Scragg R, Stewart AW, Waayer D. Effect of monthly high-dose vitamin d supplementation on cardiovascular disease in the vitamin d assessment study: A randomized clinical trial. *JAMA Cardiology* 2017; Epub ahead of print.
63. Forman JP, Giovannucci E, Holmes MD, Bischoff-Ferrari HA, Tworoger SS, Willett WC et al. Plasma 25-Hydroxyvitamin D Levels and Risk of Incident Hypertension. *Hypertension* 2007; 49: 1063–1069. <https://doi.org/10.1161/HYPERTENSIONAHA.107.087288> PMID: 17372031
64. Forman JP, Bischoff-Ferrari HA, Willett WC, Stampfer MJ, Curhan GC. Vitamin D Intake and Risk of Incident Hypertension: Results From Three Large Prospective Cohort Studies. *Hypertension* 2005; 46: 676–682. <https://doi.org/10.1161/01.HYP.0000182662.82666.37> PMID: 16144983
65. Jorde R, Figenschau Y, Emaus N, Hutchinson M, Grimnes G. Serum 25-Hydroxyvitamin D Levels Are Strongly Related to Systolic Blood Pressure But Do Not Predict Future Hypertension. *Hypertension* 2010; 55: 792–798. <https://doi.org/10.1161/HYPERTENSIONAHA.109.143990> PMID: 20065152
66. Vimalaswaran KS, Cavadino A, Berry DJ, Jorde R, Dieffenbach AK, Lu C et al. Association of vitamin D status with arterial blood pressure and hypertension risk: a mendelian randomisation study. *The Lancet Diabetes & Endocrinology* 2014; 2: 719–729.
67. Li YC, Qiao G, Uskokovic M, Xiang W, Zheng W, Kong J. Vitamin D: a negative endocrine regulator of the renin-angiotensin system and blood pressure. *J Steroid Biochem Mol Biol* 2004; 89–90: 387–392. <https://doi.org/10.1016/j.jsbmb.2004.03.004> PMID: 15225806
68. Gröbler MR, Gaksch M, Kienreich K, Verheyen N, Schmid J, Ó Hartaigh BWJ et al. Effects of Vitamin D Supplementation on Plasma Aldosterone and Renin—A Randomized Placebo-Controlled Trial. *J Clin Hypertens* 2016; n/a.
69. Resnick LM, Nicholson JP, Laragh JH. Calcium metabolism in essential hypertension: relationship to altered renin system activity. *Fed Proc* 1986; 45: 2739–2745. PMID: 3533639
70. Forman JP, Williams JS, Fisher ND. Plasma 25-Hydroxyvitamin D and Regulation of the Renin-Angiotensin System in Humans. *Hypertension* 2010; 55: 1283–1288. <https://doi.org/10.1161/HYPERTENSIONAHA.109.148619> PMID: 20351344
71. Brown JM, Williams JS, Luther JM, Garg R, Garza AE, Pojoga LH et al. Human Interventions to Characterize Novel Relationships Between the Renin-Angiotensin-Aldosterone System and Parathyroid Hormone. *Hypertension* 2014; 63: 273–280. <https://doi.org/10.1161/HYPERTENSIONAHA.113.01910> PMID: 24191286
72. Tomaschitz A, Ritz E, Pieske B, Rus-Machan J, Kienreich K, Verheyen N et al. Aldosterone and parathyroid hormone interactions as mediators of metabolic and cardiovascular disease. *Metabolism* 2014; 63: 20–31. <https://doi.org/10.1016/j.metabol.2013.08.016> PMID: 24095631
73. Wakasugi M, Noguchi T, Inoue M, Kazama Y, Tawata M, Kanemaru Y et al. Vitamin D3 stimulates the production of prostacyclin by vascular smooth muscle cells. *Prostaglandins* 1991; 42: 127–136. PMID: 1775635
74. Pittas AG, Lau J, Hu FB, Dawson-Hughes B. The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. *J Clin Endocrinol Metab* 2007; 92: 2017–2029. <https://doi.org/10.1210/jc.2007-0298> PMID: 17389701
75. Talmor Y, Golan E, Benchetrit S, Bernheim J, Klein O, Green J et al. Calcitriol blunts the deleterious impact of advanced glycation end products on endothelial cells. *Am J Physiol Renal Physiol* 2008; 294: F1059–F1064. <https://doi.org/10.1152/ajprenal.00051.2008> PMID: 18353875
76. Talmor Y, Bernheim J, Klein O, Green J, Rashid G. Calcitriol blunts pro-atherosclerotic parameters through NFκB and p38 in vitro. *European Journal Of Clinical Investigation* 2008; 38: 548–554. <https://doi.org/10.1111/j.1365-2362.2008.01977.x> PMID: 18717824
77. Kuhlmann A, Haas CS, Gross ML, Reulbach U, Holzinger M, Schwarz U et al. 1,25-Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotaly nephrectomized rat. *Am J Physiol* 2004; 286: F526–F533.
78. Witham MD, Nadir MA, Struthers AD. Effect of vitamin D on blood pressure: a systematic review and meta-analysis. *J Hypertens* 2009; 27: 1948–1954. <https://doi.org/10.1097/HJH.0b013e32832f075b> PMID: 19587609
79. Wu SH, Ho SC, Zhong L. Effects of vitamin D supplementation on blood pressure. *South Med J* 2010; 103: 729–737. <https://doi.org/10.1097/SMJ.0b013e3181e6d389> PMID: 20622727
80. Kunutsor S, Burgess S, Munroe P, Khan H. Vitamin D and high blood pressure: causal association or epiphenomenon? *Eur J Epidemiol* 2014; 29: 1–14. <https://doi.org/10.1007/s10654-013-9874-z> PMID: 24374742

81. Beveridge LA, Struthers AD, Khan F, Jorde R, Scragg R, Macdonald HM et al. Effect of Vitamin D Supplementation on Blood Pressure: A Systematic Review and Meta-analysis Incorporating Individual Patient Data. *JAMA* 2015; 175: 745–754.
82. Manousopoulou A, Al-Daghri NM, Garbis SD, Chrousos GP. Vitamin D and cardiovascular risk among adults with obesity: a systematic review and meta-analysis. *Eur J Clin Invest* 2015; 45: 1113–1126. <https://doi.org/10.1111/eci.12510> PMID: 26222607
83. Golzarand M, Shab-Bidar S, Koochakpoor G, Speakman J, Djafarian K. Effect of vitamin D3 supplementation on blood pressure in adults: An updated meta-analysis. *Nutr Metab Cardiovasc Dis* 2016; 26: 663–673. <https://doi.org/10.1016/j.numecd.2016.04.011> PMID: 27287826
84. Lee KJ, Lee YJ. Effects of vitamin D on blood pressure in patients with type 2 diabetes mellitus. *Int J Clin Pharmacol Ther* 2016; 54: 233–242. <https://doi.org/10.5414/CP202493> PMID: 26902507
85. Krause R, Buhning M, Hopfenmuller W, Holick MF, Sharma AM. Ultraviolet B and blood pressure. *The Lancet* 1998; 352: 709–710.
86. Sugden JA, Davies JL, Witham MD, Morris AD, Struthers AD. Vitamin-D improves endothelial function in patients with Type-2 diabetes mellitus and low vitamin-D levels. *Diabet Med* 2008; 25: 320–325. <https://doi.org/10.1111/j.1464-5491.2007.02360.x> PMID: 18279409
87. Pfeifer M, Begerow B, Minne HW, Nachtigall D, Hansen C. Effects of a Short-Term Vitamin D3 and Calcium Supplementation on Blood Pressure and Parathyroid Hormone Levels in Elderly Women. *J Clin Endocrinol Metab* 2001; 86: 1633–1637. <https://doi.org/10.1210/jcem.86.4.7393> PMID: 11297596
88. Asemi Z, Hashemi T, Karamali M, Samimi M, Esmailzadeh A. Effects of vitamin D supplementation on glucose metabolism, lipid concentrations, inflammation, and oxidative stress in gestational diabetes: a double-blind randomized controlled clinical trial. *Am J Clin Nutr* 2013; 98: 1425–1432. <https://doi.org/10.3945/ajcn.113.072785> PMID: 24132976
89. Forman JP, Scott JB, Ng K, Drake BF, Suarez EG, Hayden DL et al. Effect of Vitamin D Supplementation on Blood Pressure in Blacks. *Hypertension* 2013; 61: 779–785. <https://doi.org/10.1161/HYPERTENSIONAHA.111.00659> PMID: 23487599
90. Chen WR, Liu ZY, Shi Y, Yin DW, Wang H, Sha Y et al. Vitamin D and nifedipine in the treatment of Chinese patients with grades I-II essential hypertension: A randomized placebo-controlled trial. *Atherosclerosis* 2014; 235: 102–109. <https://doi.org/10.1016/j.atherosclerosis.2014.04.011> PMID: 24942709
91. Tabesh M, Azadbakht L, Faghihimani E, Tabesh M, Esmailzadeh A. Effects of calcium-vitamin D co-supplementation on metabolic profiles in vitamin D insufficient people with type 2 diabetes: a randomized controlled clinical trial. *Diabetologia* 2014; 57: 2038–2047. <https://doi.org/10.1007/s00125-014-3313-x> PMID: 25005333
92. Mozaffari-Khosravi H, Loloei S, Mirjalili MR, Barzegar K. The effect of vitamin D supplementation on blood pressure in patients with elevated blood pressure and vitamin D deficiency: a randomized, double-blind, placebo-controlled trial. *Blood Pressure Monitoring* 2015; 20: 83–91. <https://doi.org/10.1097/MBP.0000000000000091> PMID: 25350782
93. Veloudi P, Jones G, Sharman JE. Effectiveness of Vitamin D Supplementation for Cardiovascular Health Outcomes. *Pulse* 2016; 4: 193–207. <https://doi.org/10.1159/000452742> PMID: 28229054
94. Scragg R, Sowers M, Bell C. Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the Third National Health and Nutrition Examination Survey. *Diabetes Care* 2004; 27: 2813–2818. PMID: 15562190
95. Mattila C, Knekt P, Mannisto S, Rissanen H, Laaksonen MA, Montonen J et al. Serum 25-hydroxyvitamin D concentration and subsequent risk of type 2 diabetes. *Diabetes Care* 2007; 30: 2569–2570. <https://doi.org/10.2337/dc07-0292> PMID: 17626891
96. Pittas AG, Dawson-Hughes B, Li T, van Dam RM, Willett WC, Manson JE et al. Vitamin D and Calcium Intake in Relation to Type 2 Diabetes in Women. *Diabetes Care* 2006; 29: 650–656. PMID: 16505521
97. Knekt P, Laaksonen M, Mattila C, Harkanen T, Marniemi J, Heliovaara M et al. Serum Vitamin D and Subsequent Occurrence of Type 2 Diabetes. *Epidemiology* 2008; 19: 666–671. <https://doi.org/10.1097/EDE.0b013e318176b8ad> PMID: 18496468
98. Cigolini M, Iagulli MP, Miconi V, Galiotto M, Lombardi S, Targher G. Serum 25-hydroxyvitamin D3 concentrations and prevalence of cardiovascular disease among type 2 diabetic patients. *Diabetes Care* 2006; 29: 722–724. PMID: 16505539
99. Martins D, Wolf M, Pan D, Zadshir A, Tareen N, Thadhani R et al. Prevalence of Cardiovascular Risk Factors and the Serum Levels of 25-Hydroxyvitamin D in the United States: Data From the Third National Health and Nutrition Examination Survey. *Arch Intern Med* 2007; 167: 1159–1165. <https://doi.org/10.1001/archinte.167.11.1159> PMID: 17563024

100. Gupta AK, Brashear MM, Johnson WD. Prediabetes and prehypertension in healthy adults are associated with low vitamin D levels. *Diabetes Care* 2011; 34: 658–660. <https://doi.org/10.2337/dc10-1829> PMID: 21282345
101. Barengolts E. Vitamin D role and use in prediabetes. *Endocr Pract* 2010; 16: 476–485. <https://doi.org/10.4158/EP09195.RA> PMID: 20150028
102. Deleskog A, Hilding A, Brismar K, Hamsten A, Efendic S, Ostenson CG. Low serum 25-hydroxyvitamin D level predicts progression to type 2 diabetes in individuals with prediabetes but not with normal glucose tolerance. *Diabetologia* 2012; 55: 1668–1678. <https://doi.org/10.1007/s00125-012-2529-x> PMID: 22426800
103. Wimalawansa SJ. Associations of vitamin D with insulin resistance, obesity, type 2 diabetes, and metabolic syndrome. *The Journal of Steroid Biochemistry and Molecular Biology* 2016.
104. Ishida H, Norman AW. Demonstration of a high affinity receptor for 1,25-dihydroxyvitamin D3 in rat pancreas. *Mol Cell Endocrinol* 1988; 60: 109–117. PMID: 2850952
105. Bland R, Markovic D, Hills CE, Hughes SV, Chan SL, Squires PE et al. Expression of 25-hydroxyvitamin D3-1 α -hydroxylase in pancreatic islets. *J Steroid Biochem Mol Biol* 2004; 89–90: 121–125. <https://doi.org/10.1016/j.jsmb.2004.03.115> PMID: 15225758
106. Norman AW, Frankel JB, Heldt AM, Grodsky GM. Vitamin D deficiency inhibits pancreatic secretion of insulin. *Science* 1980; 209: 823–825. PMID: 6250216
107. Cade C, Norman AW. Vitamin D3 improves impaired glucose tolerance and insulin secretion in the vitamin D-deficient rat in vivo. *Endocrinology* 1986; 119: 84–90. <https://doi.org/10.1210/endo-119-1-84> PMID: 3013599
108. Chertow BS, Sivitz WI, Baranetsky NG, Clark SA, Waite A, DeLuca HF. Cellular mechanisms of insulin release: the effects of vitamin D deficiency and repletion on rat insulin secretion. *Endocrinology* 1983; 113: 1511–1518. <https://doi.org/10.1210/endo-113-4-1511> PMID: 6352248
109. George PS, Pearson ER, Witham MD. Effect of vitamin D supplementation on glycaemic control and insulin resistance: a systematic review and meta-analysis. *Diabet Med* 2012; 29: e142–e150. <https://doi.org/10.1111/j.1464-5491.2012.03672.x> PMID: 22486204
110. Nigil Haroon N, Anton A, John J, Mittal M. Effect of vitamin D supplementation on glycemic control in patients with type 2 diabetes: a systematic review of interventional studies. *J Diabetes Metab Disord* 2015; 14: 3. <https://doi.org/10.1186/s40200-015-0130-9> PMID: 25722966
111. Jamka M, Wozniwicz M, Jeszka J, Mardas M, Bogdanski P, Stelmach-Mardas M. The effect of vitamin D supplementation on insulin and glucose metabolism in overweight and obese individuals: systematic review with meta-analysis. *Scientific Reports* 2015; 5: 16142. <https://doi.org/10.1038/srep16142> PMID: 26543018
112. Mitri J, Muraru MD, Pittas AG. Vitamin D and type 2 diabetes: a systematic review. *Eur J Clin Nutr* 2011; 65: 1005–1015. <https://doi.org/10.1038/ejcn.2011.118> PMID: 21731035
113. Rosen CJ, Adams JS, Bikle DD, Black DM, Demay MB, Manson JE et al. The Nonskeletal Effects of Vitamin D: An Endocrine Society Scientific Statement. *Endocr Rev* 2012; 33: 456–492. <https://doi.org/10.1210/er.2012-1000> PMID: 22596255
114. Pittas AG, Harris SS, Stark PC, Dawson-Hughes B. The Effects of Calcium and Vitamin D Supplementation on Blood Glucose and Markers of Inflammation in Nondiabetic Adults. *Diabetes Care* 2007; 30: 980–986. <https://doi.org/10.2337/dc06-1994> PMID: 17277040
115. de Boer IH, Tinker LF, Connelly S, Curb JD, Howard BV, Kestenbaum B et al. Calcium plus vitamin D supplementation and the risk of incident diabetes in the Women's Health Initiative. *Diabetes Care* 2008; 31: 701–707. <https://doi.org/10.2337/dc07-1829> PMID: 18235052
116. Avenell A, Cook JA, MacLennan GS, McPherson GC. Vitamin D supplementation and type 2 diabetes: a substudy of a randomised placebo-controlled trial in older people (RECORD trial). *Age Ageing* 2009; 38: 606–609. <https://doi.org/10.1093/ageing/afp109> PMID: 19617604
117. Davidson MB, Duran P, Lee ML, Friedman TC. High-Dose Vitamin D Supplementation in People With Prediabetes and Hypovitaminosis D. *Diabetes Care* 2013; 36: 260–266. <https://doi.org/10.2337/dc12-1204> PMID: 23033239
118. Bell NH, Epstein S, Greene A. Evidence for alteration of the vitamin D-endocrine system in obese subjects. *J Clin Invest* 1985; 76: 370–373. <https://doi.org/10.1172/JCI111971> PMID: 2991340
119. Liel Y, Ulmer E, Shary J, Hollis BW, Bell NH. Low circulating vitamin D in obesity. *Calcif Tissue Int* 1988; 43: 199–201. PMID: 3145124
120. Buffington C, Walker B, Cowan GS Jr., Scruggs D. Vitamin D Deficiency in the Morbidly Obese. *Obes Surg* 1993; 3: 421–424. <https://doi.org/10.1381/096089293765559142> PMID: 10757956

121. Parikh SJ, Edelman M, Uwaifo GI, Freedman RJ, Semega-Janneh M, Reynolds J et al. The Relationship between Obesity and Serum 1,25-Dihydroxy Vitamin D Concentrations in Healthy Adults. *J Clin Endocrinol Metab* 2004; 89: 1196–1199. <https://doi.org/10.1210/jc.2003-031398> PMID: 15001609
122. Haddad JG, Matsuoka LY, Hollis BW, Hu YZ, Wortsman J. Human plasma transport of vitamin D after its endogenous synthesis. *J Clin Invest* 1993; 91: 2552–2555. <https://doi.org/10.1172/JCI116492> PMID: 8390483
123. Drincic AT, Armas LAG, Van Diest EE, Heaney RP. Volumetric Dilution, Rather Than Sequestration Best Explains the Low Vitamin D Status of Obesity. *Obesity Res* 2012.
124. Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF. Decreased bioavailability of vitamin D in obesity. *Am J Clin Nutr* 2000; 72: 690–693. PMID: 10966885
125. Kull M, Kallikorm R, Lember M. Body mass index determines sunbathing habits: implications on vitamin D levels. *Intern Med J* 2009; 39: 256–258. <https://doi.org/10.1111/j.1445-5994.2009.01900.x> PMID: 19402866
126. Vimalaswaran KS, Berry DJ, Lu C, Tikkanen E, Pilz S, Hiraki LT et al. Causal relationship between obesity and vitamin D status: bi-directional Mendelian randomization analysis of multiple cohorts. *PLoS Med* 2013; 10: e1001383. <https://doi.org/10.1371/journal.pmed.1001383> PMID: 23393431
127. Kamei Y, Kawada T, Kazuki R, Ono T, Kato S, Sugimoto E. Vitamin D receptor gene expression is up-regulated by 1, 25-dihydroxyvitamin D3 in 3T3-L1 preadipocytes. *Biochem Biophys Res Commun* 1993; 193: 948–955. <https://doi.org/10.1006/bbrc.1993.1717> PMID: 7686756
128. Li J, Byrne ME, Chang E, Jiang Y, Donkin SS, Buhman KK et al. 1 α ,25-Dihydroxyvitamin D hydroxylase in adipocytes. *J Steroid Biochem Mol Biol* 2008; 112: 122–126. <https://doi.org/10.1016/j.jsbmb.2008.09.006> PMID: 18840526
129. Earthman CP, Beckman LM, Masodkar K, Sibley SD. The link between obesity and low circulating 25-hydroxyvitamin D concentrations: considerations and implications. *Int J Obes (Lond)* 2012; 36: 387–396.
130. Querfeld U, Hoffmann MM, Klaus G, Eifinger F, Ackerschott M, Michalk D et al. Antagonistic effects of vitamin D and parathyroid hormone on lipoprotein lipase in cultured adipocytes. *J Am Soc Nephrol* 1999; 10: 2158–2164. PMID: 10505692
131. McCarty MF, Thomas CA. PTH excess may promote weight gain by impeding catecholamine-induced lipolysis-implications for the impact of calcium, vitamin D, and alcohol on body weight. *Medical Hypotheses* 2003; 61: 535–542. PMID: 14592784
132. Fontana L, Eagon JC, Trujillo ME, Scherer PE, Klein S. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. *Diabetes* 2007; 56: 1010–1013. <https://doi.org/10.2337/db06-1656> PMID: 17287468
133. Riek AE, Oh J, Bernal-Mizrachi C. Vitamin D regulates macrophage cholesterol metabolism in diabetes. *J Steroid Biochem Mol Biol* 2010; 121: 430–433. <https://doi.org/10.1016/j.jsbmb.2010.03.018> PMID: 20338238
134. Jorde R, Sneve M, Torjesen PA, Figenschau Y, Goransson LG, Omdal R. No effect of supplementation with cholecalciferol on cytokines and markers of inflammation in overweight and obese subjects. *Cytokine* 2010; 50: 175–180. <https://doi.org/10.1016/j.cyto.2009.12.006> PMID: 20122848
135. Wamberg L, Kampmann U, Stødkilde-Jørgensen H, Rejnmark L, Pedersen SB, Richelsen B. Effects of vitamin D supplementation on body fat accumulation, inflammation, and metabolic risk factors in obese adults with low vitamin D levels—Results from a randomized trial. *Eur J Intern Med* 2013; 24: 644–649. <https://doi.org/10.1016/j.ejim.2013.03.005> PMID: 23566943
136. Soares MJ, Chan She Ping-Delfos W, Ghanbari MH. Calcium and vitamin D for obesity: a review of randomized controlled trials. *Eur J Clin Nutr* 2011; 65: 994–1004. <https://doi.org/10.1038/ejcn.2011.106> PMID: 21731038
137. Pathak K, Soares MJ, Calton EK, Zhao Y, Hallett J. Vitamin D supplementation and body weight status: a systematic review and meta-analysis of randomized controlled trials. *Obes Rev* 2014; 15: 528–537. <https://doi.org/10.1111/obr.12162> PMID: 24528624
138. Chandler PD, Wang L, Zhang X, Sesso HD, Moorthy MV, Obi O et al. Effect of vitamin D supplementation alone or with calcium on adiposity measures: a systematic review and meta-analysis of randomized controlled trials. *Nutr Rev* 2015; 73: 577. <https://doi.org/10.1093/nutrit/nuv012> PMID: 26180255
139. Ljunghall S, Lind L, Lithell H, Skarfors E, Selinus I, Sorensen OH et al. Treatment with one-alpha-hydroxycholecalciferol in middle-aged men with impaired glucose tolerance—a prospective randomized double-blind study. *Acta Med Scand* 1987; 222: 361–367. PMID: 3321925
140. Caan B, Neuhauser M, Aragaki A, Lewis CB, Jackson R, Leboff MS et al. Calcium plus vitamin D supplementation and the risk of postmenopausal weight gain. *Arch Intern Med* 2007; 167: 893–902. <https://doi.org/10.1001/archinte.167.9.893> PMID: 17502530

141. Maki KC, Rubin MR, Wong LG, McManus JF, Jensen CD, Lawless A. Effects of vitamin D supplementation on 25-hydroxyvitamin D, high-density lipoprotein cholesterol, and other cardiovascular disease risk markers in subjects with elevated waist circumference. *Int J Food Sci Nutr* 2011; 62: 318–327. <https://doi.org/10.3109/09637486.2010.536146> PMID: 21250901
142. Sneve M, Figenschau Y, Jorde R. Supplementation with cholecalciferol does not result in weight reduction in overweight and obese subjects. *Eur J Endocrinol* 2008; 159: 675–684. <https://doi.org/10.1530/EJE-08-0339> PMID: 19056900
143. Zittermann A, Frisch S, Berthold HK, Götting C, Kuhn J, Kleesiek K et al. Vitamin D supplementation enhances the beneficial effects of weight loss on cardiovascular disease risk markers. *Am J Clin Nutr* 2009; 89: 1321–1327. <https://doi.org/10.3945/ajcn.2008.27004> PMID: 19321573
144. Salehpour A, Hosseiniapanah F, Shidfar F, Vafa M, Razaghi M, Dehghani S et al. A 12-week double-blind randomized clinical trial of vitamin D3 supplementation on body fat mass in healthy overweight and obese women. *Nutrition Journal* 2012; 11: 78. <https://doi.org/10.1186/1475-2891-11-78> PMID: 22998754
145. Carrillo AE, Flynn MG, Pinkston C, Markofski MM, Jiang Y, Donkin SS et al. Impact of vitamin D supplementation during a resistance training intervention on body composition, muscle function, and glucose tolerance in overweight and obese adults. *Clin Nutr* 2013; 32: 375–381. <https://doi.org/10.1016/j.clnu.2012.08.014> PMID: 23034474
146. Mason C, Xiao L, Imayama I, Duggan C, Wang CY, Korde L et al. Vitamin D3 supplementation during weight loss: a double-blind randomized controlled trial. *Am J Clin Nutr* 2014; 99: 1015–1025. <https://doi.org/10.3945/ajcn.113.073734> PMID: 24622804
147. Bodnar LM, Simhan HN, Powers RW, Frank MP, Cooperstein E, Roberts JM. High Prevalence of Vitamin D Insufficiency in Black and White Pregnant Women Residing in the Northern United States and Their Neonates. *J Nutr* 2007; 137: 447–452. PMID: 17237325
148. Dijkstra SH, van Beek A, Janssen JW, de Vleeschouwer LHM, Huysman WA, van den Akker ELT. High prevalence of vitamin D deficiency in newborn infants of high-risk mothers. *Arch Dis Child* 2007; 92: 750–753. <https://doi.org/10.1136/adc.2006.105577> PMID: 17715438
149. Moller UK, Ramlau-Hansen CH, Rejnmark L, Heickendorff L, Henriksen TB, Mosekilde L. Postpartum vitamin D insufficiency and secondary hyperparathyroidism in healthy Danish women. *Eur J Clin Nutr* 2006; 60: 1214–1221. <https://doi.org/10.1038/sj.ejcn.1602440> PMID: 16721399
150. Aghajafari F, Nagulesapillai T, Ronksley PE, Tough S. Association between maternal serum 25-hydroxyvitamin D level and pregnancy and neonatal outcomes: systematic review and meta-analysis of observational studies. *BMJ* 2013; 346.
151. Wei SQ, Qi HP, Luo ZC, Fraser WD. Maternal vitamin D status and adverse pregnancy outcomes: a systematic review and meta-analysis. *The Journal of Maternal-Fetal & Neonatal Medicine* 2013; 26: 889–899.
152. Shin JS, Choi MY, Longtine MS, Nelson DM. Vitamin D effects on pregnancy and the placenta. *Placenta* 2010; 31: 1027–1034. <https://doi.org/10.1016/j.placenta.2010.08.015> PMID: 20863562
153. Liu NQ, Kaplan AT, Lagishetty V, Ouyang YB, Ouyang Y, Simmons CF et al. Vitamin D and the Regulation of Placental Inflammation. *J Immunol* 2011; 186: 5968–5974. <https://doi.org/10.4049/jimmunol.1003332> PMID: 21482732
154. Thorne-Lyman A, Fawzi WW. Vitamin D During Pregnancy and Maternal, Neonatal and Infant Health Outcomes: A Systematic Review and Meta-analysis. *Paediatric and Perinatal Epidemiology* 2012; 26: 75–90. <https://doi.org/10.1111/j.1365-3016.2012.01283.x> PMID: 22742603
155. De-Regil LM, Palacios C, Ansary A, Kulier R, Pena-Rosas JP. Vitamin D supplementation for women during pregnancy. *Cochrane Database Syst Rev* 2012; CD008873. <https://doi.org/10.1002/14651858.CD008873.pub2> PMID: 22336854
156. Christesen HT, Falkenberg T, Lamont RF, Jorgensen JS. The impact of vitamin D on pregnancy: a systematic review. *Acta Obstet Gynecol Scand* 2012; 91: 1357–1367. <https://doi.org/10.1111/aogs.12000> PMID: 22974137
157. Harvey NC, Holroyd C, Ntani G, Javaid K, Cooper P, Moon R et al. Vitamin D supplementation in pregnancy: A systematic review. *Health Technol Assess* 2014; 18: 1–190.
158. Pérez-López FR, Pasupuleti V, Mezones-Holguin E, Benites-Zapata VA, Thota P, Deshpande A et al. Effect of vitamin D supplementation during pregnancy on maternal and neonatal outcomes: a systematic review and meta-analysis of randomized controlled trials. *Fertility and Sterility* 2015; 103: 1278–1288. <https://doi.org/10.1016/j.fertnstert.2015.02.019> PMID: 25813278
159. De-Regil LM, Palacios C, Lombardo LK, Pena-Rosas JP. Vitamin D supplementation for women during pregnancy. *Cochrane Database of Systematic Reviews* 2016; CD008873. <https://doi.org/10.1002/14651858.CD008873.pub3> PMID: 26765344

160. Mallet E, Gugi B, Brunelle P, Henocq A, Basuyau JP, Lemeur H. Vitamin D supplementation in pregnancy: a controlled trial of two methods. *Obstet Gynecol* 1986; 68: 300–304. PMID: [3755517](#)
161. Kaur J, Marya RK, Rathee S, Lal H, Singh GP. Effect of pharmacological doses of vitamin D during pregnancy on placental protein status and birth weight. *Nutr Res* 1991; 11: 1077–1081.
162. Hashemipour S, Ziaee A, Javadi A, Movahed F, Elmizadeh K, Javadi EH et al. Effect of treatment of vitamin D deficiency and insufficiency during pregnancy on fetal growth indices and maternal weight gain: a randomized clinical trial. *Eur J Obstet Gynecol Reprod Biol* 2014; 172: 15–19. <https://doi.org/10.1016/j.ejogrb.2013.10.010> PMID: [24210789](#)
163. Sablok A, Batra A, Thariani K, Batra A, Bharti R, Aggarwal AR et al. Supplementation of vitamin D in pregnancy and its correlation with feto-maternal outcome. *Clin Endocrinol* 2015; 83: 536–541.
164. Hollis BW, Johnson D, Hulsey TC, Ebeling M, Wagner CL. Vitamin D supplementation during pregnancy: Double blind, randomized clinical trial of safety and effectiveness. *J Bone Min Res* 2011; 26: 2341–2357.
165. Roth D, Al Mahmud A, Raqib R, Akhtar E, Perumal N, Pezzack B et al. Randomized placebo-controlled trial of high-dose prenatal third-trimester vitamin D3 supplementation in Bangladesh: the AViDD trial. *Nutrition Journal* 2013; 12: 47. <https://doi.org/10.1186/1475-2891-12-47> PMID: [23587190](#)
166. Hossain N, Kanani FH, Ramzan S, Kausar R, Ayaz S, Khanani R et al. Obstetric and neonatal outcomes of maternal vitamin D supplementation: results of an open-label, randomized controlled trial of antenatal vitamin D supplementation in Pakistani women. *J Clin Endocrinol Metab* 2014; 99: 2448–2455. <https://doi.org/10.1210/jc.2013-3491> PMID: [24646102](#)
167. Brooke OG, Brown IR, Bone CD, Carter ND, Cleeve HJ, Maxwell JD et al. Vitamin D supplements in pregnant Asian women: effects on calcium status and fetal growth. *Br Med J* 1980; 280: 751–754. PMID: [6989438](#)
168. Karras SN, Anagnostis P, Naughton D, Annweiler C, Petroczi A, Goulis DG. Vitamin D during pregnancy: why observational studies suggest deficiency and interventional studies show no improvement in clinical outcomes? A narrative review. *Journal of endocrinological investigation* 2015; 38: 1265–1275. <https://doi.org/10.1007/s40618-015-0363-y> PMID: [26219612](#)
169. Giuliano AR, Franceschi RT, Wood RJ. Characterization of the vitamin D receptor from the Caco-2 human colon carcinoma cell line: effect of cellular differentiation. *Arch Biochem Biophys* 1991; 285: 261–269. PMID: [1654769](#)
170. Ingraham BA, Bragdon B, Nohe A. Molecular basis of the potential of vitamin D to prevent cancer. *Curr Med Res Opin* 2008; 24: 139–149. <https://doi.org/10.1185/030079908X253519> PMID: [18034918](#)
171. Giovannucci E, Liu Y, Rimm EB, Hollis BW, Fuchs CS, Stampfer MJ et al. Prospective Study of Predictors of Vitamin D Status and Cancer Incidence and Mortality in Men. *J Natl Cancer Inst* 2006; 98: 451–459. <https://doi.org/10.1093/jnci/dji101> PMID: [16595781](#)
172. Smedby KE, Hjalgrim H, Melbye M, Torrang A, Rostgaard K, Munksgaard L et al. Ultraviolet Radiation Exposure and Risk of Malignant Lymphomas. *J Natl Cancer Inst* 2005; 97: 199–209. <https://doi.org/10.1093/jnci/dji022> PMID: [15687363](#)
173. Abbas S, Linseisen J, Chang-Claude J. Dietary vitamin D and calcium intake and premenopausal breast cancer risk in a German case-control study. *Nutr Cancer* 2007; 59: 54–61. <https://doi.org/10.1080/01635580701390223> PMID: [17927502](#)
174. Xu Y, He B, Pan Y, Deng Q, Sun H, Li R et al. Systematic review and meta-analysis on vitamin D receptor polymorphisms and cancer risk. *Tumor Biol* 2014; 35: 4153–4169.
175. Moukayed M, Grant WB. The roles of UVB and vitamin D in reducing risk of cancer incidence and mortality: A review of the epidemiology, clinical trials, and mechanisms. *Reviews in Endocrine and Metabolic Disorders* 2017; 1–16.
176. Gorham ED, Garland CF, Garland FC, Grant WB, Mohr SB, Lipkin M et al. Vitamin D and prevention of colorectal cancer. *The Journal of Steroid Biochemistry and Molecular Biology* 2005; 97: 179–194. <https://doi.org/10.1016/j.jsbmb.2005.06.018> PMID: [16236494](#)
177. Gorham ED, Garland CF, Garland FC, Grant WB, Mohr SB, Lipkin M et al. Optimal vitamin D status for colorectal cancer prevention: a quantitative meta analysis. *Am J Prev Med* 2007; 32: 210–216. <https://doi.org/10.1016/j.amepre.2006.11.004> PMID: [17296473](#)
178. Chen P, Hu P, Xie D, Qin Y, Wang F, Wang H. Meta-analysis of vitamin D, calcium and the prevention of breast cancer. *Breast Cancer Research and Treatment* 2009.
179. Klampfer L. Vitamin D and colon cancer. *World J Gastrointest Oncol* 2014; 6: 430–437. <https://doi.org/10.4251/wjgo.v6.i11.430> PMID: [25400874](#)
180. Feldman D, Krishnan AV, Swami S, Giovannucci E, Feldman BJ. The role of vitamin D in reducing cancer risk and progression. *Nat Rev Cancer* 2014; 14: 342–357. <https://doi.org/10.1038/nrc3691> PMID: [24705652](#)

181. Li M, Chen P, Li J, Chu R, Xie D, Wang H. Review: The Impacts of Circulating 25-Hydroxyvitamin D Levels on Cancer Patient Outcomes: A Systematic Review and Meta-Analysis. *J Clin Endocrinol Metab* 2014; jc20134320.
182. Chung M, Balk EM, Brendel M, Ip S, Lau J, Lee J et al. Vitamin D and calcium: a systematic review of health outcomes. *Evid Rep Technol Assess (Full Rep)* 2009; 183: 1–420.
183. Chung M, Lee J, Terasawa T, Lau J, Trikalinos TA. Vitamin D With or Without Calcium Supplementation for Prevention of Cancer and Fractures: An Updated Meta-analysis for the U.S. Preventive Services Task Force. *Ann Intern Med* 2011; 155: 827–838. <https://doi.org/10.7326/0003-4819-155-12-201112200-00005> PMID: 22184690
184. Bjelakovic G, Gluud LL, Nikolova D, Whitfield K, Krstic G, Wetterslev J et al. Vitamin D supplementation for prevention of cancer in adults. *Cochrane Database Syst Rev* 2014; 6: CD007469.
185. Sperati F, Vici P, Maugeri-Sacca M, Stranges S, Santesso N, Mariani L et al. Vitamin D Supplementation and Breast Cancer Prevention: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. *PLoS ONE* 2013; 8: e69269. <https://doi.org/10.1371/journal.pone.0069269> PMID: 23894438
186. Keum N, Giovannucci E. Vitamin D supplements and cancer incidence and mortality: a meta-analysis. *Br J Cancer* 2014; 111: 976–980. <https://doi.org/10.1038/bjc.2014.294> PMID: 24918818
187. Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, Heaney RP. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. *Am J Clin Nutr* 2007; 85: 1586–1591. PMID: 17556697
188. Wactawski-Wende J, Kotchen JM, Anderson GL, Assaf AR, Brunner RL, Sullivan MJ et al. Calcium plus Vitamin D Supplementation and the Risk of Colorectal Cancer. *N Engl J Med* 2006; 354: 684–696. <https://doi.org/10.1056/NEJMoa055222> PMID: 16481636
189. Bolland MJ, Grey A, Gamble GD, Reid IR. Calcium and vitamin D supplements and health outcomes: a reanalysis of the Women's Health Initiative (WHI) limited-access data set. *The American Journal of Clinical Nutrition* 2011; 94: 1144–1149. <https://doi.org/10.3945/ajcn.111.015032> PMID: 21880848
190. Zheng Y, Zhu J, Zhou M, Cui L, Yao W, Liu Y. Meta-Analysis of Long-Term Vitamin D Supplementation on Overall Mortality. *PLoS ONE* 2013; 8: e82109. <https://doi.org/10.1371/journal.pone.0082109> PMID: 24349197
191. Avenell A, MacLennan GS, Jenkinson DJ, McPherson GC, McDonald AM, Pant PR et al. Long-Term Follow-Up for Mortality and Cancer in a Randomized Placebo-Controlled Trial of Vitamin D3 and/or Calcium (RECORD Trial). *J Clin Endocrinol Metab* 2012; 97: 614–622.
192. Lazzeroni M, Serrano D, Pilz S, Gandini S. Vitamin D supplementation and cancer: review of randomized controlled trials. *Anticancer Agents Med Chem* 2013; 13: 118–125. PMID: 23094929
193. Lappe J, Watson P, Travers-Gustafson D. Effect of vitamin d and calcium supplementation on cancer incidence in older women: A randomized clinical trial. *JAMA* 2017; 317: 1234–1243. <https://doi.org/10.1001/jama.2017.2115> PMID: 28350929
194. Grant WB, Boucher BJ. Randomized controlled trials of vitamin D and cancer incidence: A modeling study. *PLoS ONE* 2017; 12: e0176448. <https://doi.org/10.1371/journal.pone.0176448> PMID: 28459861
195. Khajavi A, Amirhakimi GH. The rachitic lung. Pulmonary findings in 30 infants and children with malnutritional rickets. *Clin Pediatr (Phila)* 1977; 16: 36–38.
196. Martineau AR, Honecker FU, Wilkinson RJ, Griffiths CJ. Vitamin D in the treatment of pulmonary tuberculosis. *J Steroid Biochem Mol Biol* 2007; 103: 793–798. <https://doi.org/10.1016/j.jsbmb.2006.12.052> PMID: 17223549
197. Cannell JJ. Epidemic influenza and vitamin D. *Epidemiol Infect* 2006; 134: 1129–1140. <https://doi.org/10.1017/S0950268806007175> PMID: 16959053
198. Reichert TA, Simonsen L, Sharma A, Pardo SA, Fedson DS, Miller MA. Influenza and the winter increase in mortality in the United States, 1959–1999. *Am J Epidemiol* 2004; 160: 492–502. <https://doi.org/10.1093/aje/kwh227> PMID: 15321847
199. Black RE, Cousens S, Johnson HL, Lawn JE, Rudan I, Bassani DG et al. Global, regional, and national causes of child mortality in 2008: a systematic analysis. *Lancet* 2010; 375: 1969–1987. [https://doi.org/10.1016/S0140-6736\(10\)60549-1](https://doi.org/10.1016/S0140-6736(10)60549-1) PMID: 20466419
200. Liu PT. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. *Science* 2006; 311: 1770–1773. <https://doi.org/10.1126/science.1123933> PMID: 16497887
201. Wang TT. Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. *J Immunol* 2004; 173: 2909–2912. PMID: 15322146
202. White JH. Vitamin D metabolism and signaling in the immune system. *Rev Endocr Metab Disord* 2012; 13: 21–29. <https://doi.org/10.1007/s11154-011-9195-z> PMID: 21845364

203. Ginde A, Mansbach J, Camargo C. Vitamin D, respiratory infections, and asthma. *Current Allergy and Asthma Reports* 2009; 9: 81–87. PMID: [19063829](#)
204. Ginde AA, Mansbach JM, Camargo CA Jr. Association between serum 25-hydroxyvitamin D level and upper respiratory tract infection in the Third National Health and Nutrition Examination Survey. *Arch Intern Med* 2009; 169: 384–390. <https://doi.org/10.1001/archinternmed.2008.560> PMID: [19237723](#)
205. Laaksi I, Ruohola JP, Tuohimaa P, Auvinen A, Haataja R, Pihlajamäki H et al. An association of serum vitamin D concentrations < 40 nmol/L with acute respiratory tract infection in young Finnish men. *Am J Clin Nutr* 2007; 86: 714–717. PMID: [17823437](#)
206. Sabetta JR, DePetrillo P, Cipriani RJ, Smardin J, Burns LA, Landry ML. Serum 25-Hydroxyvitamin D and the Incidence of Acute Viral Respiratory Tract Infections in Healthy Adults. *PLoS ONE* 2010; 5: e11088. <https://doi.org/10.1371/journal.pone.0011088> PMID: [20559424](#)
207. Science M, Maguire JL, Russell ML, Smieja M, Walter SD, Loeb M. Low serum 25-hydroxyvitamin D level and risk of upper respiratory tract infection in children and adolescents. *Clin Infect Dis* 2013; 57: 392–397. <https://doi.org/10.1093/cid/cit289> PMID: [23677871](#)
208. Berry DJ, Hesketh K, Power C, Hyppönen E. Vitamin D status has a linear association with seasonal infections and lung function in British adults. *Br J Nutr* 2011; 106: 1433–1440. <https://doi.org/10.1017/S0007114511001991> PMID: [21736791](#)
209. Bryson KJ, Nash AA, Norval M. Does vitamin D protect against respiratory viral infections? *Epidemiol Infect* 2014; 142: 1789–1801. <https://doi.org/10.1017/S0950268814000193> PMID: [25030183](#)
210. Yamshchikov AV, Desai NS, Blumberg HM, Ziegler TR, Tangpricha V. Vitamin D for treatment and prevention of infectious diseases: a systematic review of randomized controlled trials. *Endocr Pract* 2009; 15: 438–449. <https://doi.org/10.4158/EP09101.ORR> PMID: [19491064](#)
211. Charan J, Goyal JP, Saxena D, Yadav P. Vitamin D for prevention of respiratory tract infections: A systematic review and meta-analysis. *J Pharmacol Pharmacother* 2012; 3: 300–303. <https://doi.org/10.4103/0976-500X.103685> PMID: [23326099](#)
212. Bergman P, Lindh ÅU, Björkhem-Bergman L, Lindh JD. Vitamin D and Respiratory Tract Infections: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *PLoS ONE* 2013; 8: e65835. <https://doi.org/10.1371/journal.pone.0065835> PMID: [23840373](#)
213. Mao S, Huang S. Vitamin D supplementation and risk of respiratory tract infections: A meta-analysis of randomized controlled trials. *Scand J Infect Dis* 2013; 45: 696–702. <https://doi.org/10.3109/00365548.2013.803293> PMID: [23815596](#)
214. Das RR, Singh M, Panigrahi I, Naik SS. Vitamin d supplementation for the treatment of acute childhood pneumonia: a systematic review. *ISRN Pediatr* 2013; 2013: 459160.
215. Jolliffe DA, Griffiths CJ, Martineau AR. Vitamin D in the prevention of acute respiratory infection: Systematic review of clinical studies. *The Journal of Steroid Biochemistry and Molecular Biology* 2013; 136: 321–329. <https://doi.org/10.1016/j.jsbmb.2012.11.017> PMID: [23220552](#)
216. Xiao L, Xing C, Yang Z, Xu S, Wang M, Du H et al. Vitamin D supplementation for the prevention of childhood acute respiratory infections: a systematic review of randomised controlled trials. *Br J Nutr* 2015; 114: 1026–1034. <https://doi.org/10.1017/S000711451500207X> PMID: [26310436](#)
217. Yakoob MY, Salam RA, Khan FR, Bhutta ZA. Vitamin D supplementation for preventing infections in children under five years of age. *Cochrane Database of Systematic Reviews* 2016; CD008824. <https://doi.org/10.1002/14651858.CD008824.pub2> PMID: [27826955](#)
218. Vuichard Gysin D, Dao D, Gysin CM, Lytvyn L, Loeb M. Effect of Vitamin D3 Supplementation on Respiratory Tract Infections in Healthy Individuals: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *PLoS ONE* 2016; 11: e0162996. <https://doi.org/10.1371/journal.pone.0162996> PMID: [27631625](#)
219. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? *Control Clin Trials* 1996; 17: 1–12. PMID: [8721797](#)
220. Manaseki-Holland S, Maroof Z, Bruce J, Mughal MZ, Masher MI, Bhutta ZA et al. Effect on the incidence of pneumonia of vitamin D supplementation by quarterly bolus dose to infants in Kabul: a randomised controlled superiority trial. *Lancet* 2012; 379: 1419–1427. [https://doi.org/10.1016/S0140-6736\(11\)61650-4](https://doi.org/10.1016/S0140-6736(11)61650-4) PMID: [22494826](#)
221. Kumar GT, Sachdev HS, Chellani H, Rehman AM, Singh V, Arora H et al. Effect of weekly vitamin D supplements on mortality, morbidity, and growth of low birthweight term infants in India up to age 6 months: randomised controlled trial. *BMJ* 2011; 342: d2975. <https://doi.org/10.1136/bmj.d2975> PMID: [21628364](#)

222. Garcion E, Wion-Barbot N, Montero-Menei CN, Berger F, Wion D. New clues about vitamin D functions in the nervous system. *Trends in Endocrinology and Metabolism* 2002; 13: 100–105. PMID: [11893522](#)
223. Zehnder D, Bland R, Williams MC, McNinch RW, Howie AJ, Stewart PM et al. Extrarenal expression of 25-hydroxyvitamin d(3)-1 alpha-hydroxylase. *J Clin Endocrinol Metab* 2001; 86: 888–894. <https://doi.org/10.1210/jcem.86.2.7220> PMID: [11158062](#)
224. Eyles DW, Smith S, Kinobe R, Hewison M, McGrath JJ. Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain. *J Chem Neuroanat* 2005; 29: 21–30. <https://doi.org/10.1016/j.jchemneu.2004.08.006> PMID: [15589699](#)
225. Brachet P, Neveu I, Naveilhan P, Garcion E, Wion D (2005) Vitamin D, A Neuroactive Hormone: From Brain Development to Pathological Disorders. In: David F, Pike JW, Francis HG, editors. *Vitamin D* (2). Burlington: Academic Press. pp. 1779–1789.
226. Wion D, MacGrogan D, Neveu I, Jehan F, Houlgatte R, Brachet P. 1,25-Dihydroxyvitamin D3 is a potent inducer of nerve growth factor synthesis. *J Neurosci Res* 1991; 28: 110–114. <https://doi.org/10.1002/jnr.490280111> PMID: [1904101](#)
227. Patrick RP, Ames BN. Vitamin D and the omega-3 fatty acids control serotonin synthesis and action, part 2: relevance for ADHD, bipolar disorder, schizophrenia, and impulsive behavior. *FASEB J* 2015; 29: 2207–2222. <https://doi.org/10.1096/fj.14-268342> PMID: [25713056](#)
228. Schneider B, Weber B, Frensch A, Stein J, Fritz J. Vitamin D in schizophrenia, major depression and alcoholism. *J Neural Transm* 2000; 107: 839–842.
229. Wilkins CH, Sheline YI, Roe CM, Birge SJ, Morris JC. Vitamin D Deficiency Is Associated With Low Mood and Worse Cognitive Performance in Older Adults. *Am J Geriatr Psychiatry* 2006; 14: 1032–1040. <https://doi.org/10.1097/01.JGP.0000240986.74642.7c> PMID: [17138809](#)
230. Hoogendijk WJ, Lips P, Dik MG, Deeg DJ, Beekman AT, Penninx BW. Depression is associated with decreased 25-hydroxyvitamin D and increased parathyroid hormone levels in older adults. *Arch Gen Psychiatry* 2008; 65: 508–512. <https://doi.org/10.1001/archpsyc.65.5.508> PMID: [18458202](#)
231. Jorde R, Waterloo K, Saleh F, Haug E, Svartberg J. Neuropsychological function in relation to serum parathyroid hormone and serum 25-hydroxyvitamin D levels. *J Neurol* 2006; 253: 464–470. <https://doi.org/10.1007/s00415-005-0027-5> PMID: [16283099](#)
232. Jaddou HY, Batieha AM, Khader YS, Kanaan SH, El-Khateeb MS, Ajlouni KM. Depression is associated with low levels of 25-hydroxyvitamin D among Jordanian adults: results from a national population survey. *Eur Arch Psychiatry Clin Neurosci* 2012; 262: 321–327. <https://doi.org/10.1007/s00406-011-0265-8> PMID: [21993566](#)
233. Polak MA, Houghton LA, Reeder AI, Harper MJ, Conner TS. Serum 25-hydroxyvitamin D concentrations and depressive symptoms among young adult men and women. *Nutrients* 2014; 6: 4720–4730. <https://doi.org/10.3390/nu6114720> PMID: [25353666](#)
234. Black LJ, Jacoby P, Allen KL, Trapp GS, Hart PH, Byrne SM et al. Low vitamin D levels are associated with symptoms of depression in young adult males. *Aust N Z J Psychiatry* 2014; 48: 464–471. <https://doi.org/10.1177/0004867413512383> PMID: [24226892](#)
235. Ju SY, Lee YJ, Jeong SN. Serum 25-hydroxyvitamin D levels and the risk of depression: a systematic review and meta-analysis. *J Nutr Health Aging* 2013; 17: 447–455. <https://doi.org/10.1007/s12603-012-0418-0> PMID: [23636546](#)
236. Zhao G, Ford ES, Li C, Balluz LS. No associations between serum concentrations of 25-hydroxyvitamin D and parathyroid hormone and depression among US adults. *Br J Nutr* 2010; 104: 1696–1702. <https://doi.org/10.1017/S0007114510002588> PMID: [20642877](#)
237. Nanri A, Mizoue T, Matsushita Y, Poudel-Tandukar K, Sato M, Ohta M et al. Association between serum 25-hydroxyvitamin D and depressive symptoms in Japanese: analysis by survey season. *Eur J Clin Nutr* 2009; 63: 1444–1447. <https://doi.org/10.1038/ejcn.2009.96> PMID: [19690578](#)
238. Pan A, Lu L, Franco OH, Yu Z, Li H, Lin X. Association between depressive symptoms and 25-hydroxyvitamin D in middle-aged and elderly Chinese. *J Affect Disord* 2009; 118: 240–243. <https://doi.org/10.1016/j.jad.2009.02.002> PMID: [19249103](#)
239. Spedding S. Vitamin D and depression: a systematic review and meta-analysis comparing studies with and without biological flaws. *Nutrients* 2014; 6: 1501–1518. <https://doi.org/10.3390/nu6041501> PMID: [24732019](#)
240. Li G, Mbuagbaw L, Samaan Z, Falavigna M, Zhang S, Adachi JD et al. Efficacy of vitamin D supplementation in depression in adults: a systematic review. *J Clin Endocrinol Metab* 2014; 99: 757–767. <https://doi.org/10.1210/jc.2013-3450> PMID: [24423304](#)
241. Shaffer JAP, Edmondson D, Wasson LT, Falzon L, Homma K, Ezeokoli N et al. Vitamin D Supplementation for Depressive Symptoms: A Systematic Review and Meta-Analysis of Randomized Controlled

- Trials. *Psychosom Med* 2014; 76: 190–196. <https://doi.org/10.1097/PSY.000000000000044> PMID: 24632894
242. Gowda U, Mutowo MP, Smith BJ, Wluka AE, Renzaho AMN. Vitamin D supplementation to reduce depression in adults: Meta-analysis of randomized controlled trials. *Nutrition* 2015; 31: 421–429. <https://doi.org/10.1016/j.nut.2014.06.017> PMID: 25701329
243. Hoffmann MR, Senior PA, Mager DR. Vitamin D Supplementation and Health-Related Quality of Life: A Systematic Review of the Literature. *Journal of the Academy of Nutrition and Dietetics* 2015; 115: 406–418. <https://doi.org/10.1016/j.jand.2014.10.023> PMID: 25573654
244. Okereke OI, Singh A. The role of vitamin D in the prevention of late-life depression. *Journal of Affective Disorders* 2016; 198: 1–14. <https://doi.org/10.1016/j.jad.2016.03.022> PMID: 26998791
245. Harris S, Dawson-Hughes B. Seasonal mood changes in 250 normal women. *Psychiatry Res* 1993; 49: 77–87. PMID: 8140183
246. Bertone-Johnson ER, Powers SI, Spangler L, Larson J, Michael YL, Millen AE et al. Vitamin D Supplementation and Depression in the Womens Health Initiative Calcium and Vitamin D Trial. *Am J Epidemiol* 2012; 176: 1–13. <https://doi.org/10.1093/aje/kwr482> PMID: 22573431
247. Belcaro G, Cesarone MR, Cornelli U, Dugall M. MF Afragil(R) in the treatment of 34 menopause symptoms: a pilot study. *Panminerva Med* 2010; 52: 49–54. PMID: 20657535
248. Dean AJ, Bellgrove MA, Hall T, Phan WMJ, Eyles DW, Kvaskoff D et al. Effects of Vitamin D Supplementation on Cognitive and Emotional Functioning in Young Adults—A Randomised Controlled Trial. *PLoS ONE* 2011; 6: e25966. <https://doi.org/10.1371/journal.pone.0025966> PMID: 22073146
249. Khajehei M, Abdali K, Parsanezhad ME, Tabatabaee HR. Effect of treatment with dydrogesterone or calcium plus vitamin D on the severity of premenstrual syndrome. *Int J Gynaecol Obstet* 2009; 105: 158–161. <https://doi.org/10.1016/j.ijgo.2009.01.016> PMID: 19232611
250. Yalamanchili V, Gallagher JC. Treatment with hormone therapy and calcitriol did not affect depression in older postmenopausal women: no interaction with estrogen and vitamin D receptor genotype polymorphisms. *Menopause* 2012; 19: 697–703. <https://doi.org/10.1097/gme.0b013e31823bcec5> PMID: 22205149
251. Dumville JC, Miles JN, Porthouse J, Cockayne S, Saxon L, King C. Can vitamin D supplementation prevent winter-time blues? A randomised trial among older women. *J Nutr Health Aging* 2006; 10: 151–153. PMID: 16554952
252. Arvola DS, Odean MJ, Dornfeld MP, Regal RR, Arvola JG, Karwoski GC et al. Correlation of symptoms with vitamin D deficiency and symptom response to cholecalciferol treatment: a randomized controlled trial. *Endocr Pract* 2009; 15: 203–212. <https://doi.org/10.4158/EP.15.3.203> PMID: 19364687
253. Jorde R, Sneve M, Figenschau Y, Svartberg J, Waterloo K. Effects of vitamin D supplementation on symptoms of depression in overweight and obese subjects: randomized double blind trial. *J Intern Med* 2008; 264: 599–609. <https://doi.org/10.1111/j.1365-2796.2008.02008.x> PMID: 18793245
254. Lansdowne ATG, Provost SC. Vitamin D₃ enhances mood in healthy subjects during winter. *Psychopharmacology* 1998; 135: 319. PMID: 9539254
255. Vieth R, Kimball S, Hu A, Walfish P. Randomized comparison of the effects of the vitamin D₃ adequate intake versus 100 mcg (4000 IU) per day on biochemical responses and the wellbeing of patients. *Nutrition Journal* 2004; 3: 8. <https://doi.org/10.1186/1475-2891-3-8> PMID: 15260882
256. Gloth FM. Vitamin D vs broad spectrum phototherapy in the treatment of seasonal affective disorder. *J Nutr Health Aging* 1999; 3: 5–7. PMID: 10888476
257. Khoraminy N, Tehrani-Doost M, Jazayeri S, Hosseini A, Djazayeri A. Therapeutic effects of vitamin D as adjunctive therapy to fluoxetine in patients with major depressive disorder. *Aust N Z J Psychiatry* 2013; 47: 271–275. <https://doi.org/10.1177/0004867412465022> PMID: 23093054
258. Zhang M, Robitaille L, Eintracht S, Hoffer LJ. Vitamin C provision improves mood in acutely hospitalized patients. *Nutrition* 2011; 27: 530–533. <https://doi.org/10.1016/j.nut.2010.05.016> PMID: 20688474
259. Li G, Mbuagbaw L, Samaan Z, Zhang S, Adachi JD, Papaioannou A et al. Efficacy of vitamin D supplementation in depression in adults: a systematic review protocol. *Syst Rev* 2013; 2: 64. <https://doi.org/10.1186/2046-4053-2-64> PMID: 23927040
260. Mozaffari-Khosravi H, Nabizade L, Yassini-Ardakani SM, Hadinedoushan H, Barzegar K. The Effect of 2 Different Single Injections of High Dose of Vitamin D on Improving the Depression in Depressed Patients With Vitamin D Deficiency: A Randomized Clinical Trial. *J Clin Psychopharmacol* 2013; 33: 378–385. <https://doi.org/10.1097/JCP.0b013e31828f619a> PMID: 23609390
261. Melamed ML, Michos ED, Post W, Astor B. 25-Hydroxyvitamin D Levels and the Risk of Mortality in the General Population. *Arch Intern Med* 2008; 168: 1629–1637. <https://doi.org/10.1001/archinte.168.15.1629> PMID: 18695076

262. Pilz S, Dobnig H, Nijpels G, Heine RJ, Stehouwer CD, Snijder MB et al. Vitamin D and mortality in older men and women. *Clin Endocrinol (Oxf)* 2009; 71: 666–672.
263. Chowdhury R, Kunutsor S, Vitezova A, Oliver-Williams C, Chowdhury S, Kiefte-de-Jong JC et al. Vitamin D and risk of cause specific death: systematic review and meta-analysis of observational cohort and randomised intervention studies. *BMJ* 2014; 348: g1903. <https://doi.org/10.1136/bmj.g1903> PMID: 24690623
264. Barnard K, Colón-Emeric CS. Extraskeletal effects of vitamin D in older adults: Cardiovascular disease, mortality, mood, and cognition. *Am J Geriatr Pharmacother* 2010; 8: 4–33. <https://doi.org/10.1016/j.amjopharm.2010.02.004> PMID: 20226390
265. Pilz S, Grubler M, Gaksch M, Schwetz V, Trummer C, Hartaigh BO et al. Vitamin D and Mortality. *Anti-cancer Res* 2016; 36: 1379–1387. PMID: 26977039
266. Gaksch M, Jorde R, Grimnes G, Joakimsen R, Schirmer H, Wilsgaard T et al. Vitamin D and mortality: Individual participant data meta-analysis of standardized 25-hydroxyvitamin D in 26916 individuals from a European consortium. *PLoS ONE* 12: e0170791. <https://doi.org/10.1371/journal.pone.0170791> PMID: 28207791
267. Holick MF. Vitamin D Deficiency. *N Engl J Med* 2007; 357: 266–281. <https://doi.org/10.1056/NEJMr070553> PMID: 17634462
268. Mosekilde L. Vitamin D and the elderly. *Clin Endocrinol (Oxf)* 2005; 62: 265–281.
269. Autier P, Gandini S. Vitamin D Supplementation and Total Mortality: A Meta-analysis of Randomized Controlled Trials. *Arch Intern Med* 2007; 167: 1730–1737. <https://doi.org/10.1001/archinte.167.16.1730> PMID: 17846391
270. Bjelakovic G, Gluud LL, Nikolova D, Whitfield K, Wetterslev J, Simonetti RG et al. Vitamin D supplementation for prevention of mortality in adults. *Cochrane Database Syst Rev* 2011; CD007470. <https://doi.org/10.1002/14651858.CD007470.pub2> PMID: 21735411
271. Bjelakovic G, Gluud LL, Nikolova D, Whitfield K, Wetterslev J, Simonetti RG et al. Vitamin D supplementation for prevention of mortality in adults. *Cochrane Database Syst Rev* 2014; 1: CD007470.
272. Rejnmark L, Avenell A, Masud T, Anderson F, Meyer HE, Sanders KM et al. Vitamin D with Calcium Reduces Mortality: Patient Level Pooled Analysis of 70,528 Patients from Eight Major Vitamin D Trials. *J Clin Endocrinol Metab* 2012; 97: 2670–2681.
273. Latham NK, Anderson CS, Lee A, Bennett DA, Moseley A, Cameron ID. A randomized, controlled trial of quadriceps resistance exercise and vitamin D in frail older people: the Frailty Interventions Trial in Elderly Subjects (FITNESS). *J Am Geriatr Soc* 2003; 51: 291–299. PMID: 12588571
274. Law M, Withers H, Morris J, Anderson F. Vitamin D supplementation and the prevention of fractures and falls: results of a randomised trial in elderly people in residential accommodation. *Age Ageing* 2006; 35: 482–486. <https://doi.org/10.1093/ageing/afj080> PMID: 16641143
275. Zittermann A, Ernst JB, Prokop S, Fuchs U, Dreier J, Kuhn J et al. Effect of vitamin D on all-cause mortality in heart failure (EVITA): a 3-year randomized clinical trial with 4000 IU vitamin D daily. *Eur Heart J* 2017; Epub ahead of print.
276. Bjelakovic G, Gluud LL, Nikolova D, Whitfield K, Wetterslev J, Simonetti RG et al. Vitamin D supplementation for prevention of mortality in adults. *Cochrane Database of Systematic Reviews* 2014.
277. Zheng YT, Cui QQ, Hong YM, Yao WG. A Meta-Analysis of High Dose, Intermittent Vitamin D Supplementation among Older Adults. *PLoS ONE* 2015; 10: e0115850. <https://doi.org/10.1371/journal.pone.0115850> PMID: 25602255
278. Brenner H, Jansen L, Saum KU, Holleczer B, Schöttker B. Vitamin D Supplementation Trials Aimed at Reducing Mortality Have Much Higher Power When Focusing on People with Low Serum 25-Hydroxy-vitamin D Concentrations. *J Nutr* 2017; Epub ahead of print.
279. Jackson RD, LaCroix AZ, Gass M, Wallace RB, Robbins J, Lewis CE et al. Calcium plus vitamin D supplementation and the risk of fractures. *N Engl J Med* 2006; 354: 669–683. <https://doi.org/10.1056/NEJMoa055218> PMID: 16481635
280. Kristal AR. Are Clinical Trials the "Gold Standard" for Cancer Prevention Research? *Cancer Epidemiol Biomarkers Prev* 2008; 17: 3289. <https://doi.org/10.1158/1055-9965.EPI-08-1066> PMID: 19064540
281. Gillie OI. Controlled trials of vitamin D, causality and type 2 statistical error. *Public Health Nutr* 2016; 19: 409–414. <https://doi.org/10.1017/S1368980014002304> PMID: 25370294
282. Heaney RP. Guidelines for optimizing design and analysis of clinical studies of nutrient effects. *Nutr Rev* 2014; 72: 48–54.
283. Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. *J Clin Endocrinol Metab* 2011; 96: 53–58. <https://doi.org/10.1210/jc.2010-2704> PMID: 21118827

284. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP et al. Evaluation, Treatment, and Prevention of Vitamin D Deficiency: an Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab* 2011; 96: 1911–1930.
285. Hollis BW, Wagner CL. The Role of the Parent Compound Vitamin D with Respect to Metabolism and Function: Why Clinical Dose Intervals Can Affect Clinical Outcomes. *J Clin Endocrinol Metab* 2013; 98: 4619–4628. <https://doi.org/10.1210/jc.2013-2653> PMID: 24106283
286. Slominski AT, Kim TK, Li W, Postlethwaite A, Tieu EW, Tang EKY et al. Detection of novel CYP11A1-derived secosteroids in the human epidermis and serum and pig adrenal gland. *Sic Rep* 2015; 5: 14875.
287. Oplönder C, Volkmar CM, Paunel-Görgülü A, van Faassen EE, Heiss C, Kelm M et al. Whole Body UVA Irradiation Lowers Systemic Blood Pressure by Release of Nitric Oxide From Intracutaneous Photolabile Nitric Oxide Derivates. *Circ Res* 2009; 105: 1031. <https://doi.org/10.1161/CIRCRESAHA.109.207019> PMID: 19797169
288. Halliday GM, Byrne SN. An Unexpected Role: UVA-Induced Release of Nitric Oxide from Skin May Have Unexpected Health Benefits. *J Invest Dermatol* 2014; 134: 1791–1794. <https://doi.org/10.1038/jid.2014.33> PMID: 24924758
289. Liu D, Fernandez BO, Hamilton A, Lang NN, Gallagher JMC, Newby DE et al. UVA Irradiation of Human Skin Vasodilates Arterial Vasculature and Lowers Blood Pressure Independently of Nitric Oxide Synthase. *J Invest Dermatol* 2014; 134: 1839–1846. <https://doi.org/10.1038/jid.2014.27> PMID: 24445737
290. Hujoel PP. Vitamin D and dental caries in controlled clinical trials: systematic review and meta-analysis. *Nutr Rev* 2013; 71: 88–97. <https://doi.org/10.1111/j.1753-4887.2012.00544.x> PMID: 23356636
291. Kupferschmidt K. Uncertain Verdict as Vitamin D Goes On Trial. *Science* 2012; 337: 1476–1478. <https://doi.org/10.1126/science.337.6101.1476> PMID: 22997323
292. Manson JE, Bassuk SS, Lee IM, Cook NR, Albert MA, Gordon D et al. The VITamin D and Omega-3 Trial (VITAL): Rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. *Contemporary Clinical Trials* 2012; 33: 159–171. <https://doi.org/10.1016/j.cct.2011.09.009> PMID: 21986389
293. Bassuk SS, Manson JE, Lee IM, Cook NR, Christen WG, Bubes VY et al. Baseline characteristics of participants in the VITamin D and Omega-3 Trial (VITAL). *Contemporary Clinical Trials* 2016; 47: 235–243. <https://doi.org/10.1016/j.cct.2015.12.022> PMID: 26767629
294. Cianferotti L, Bertoldo F, Bischoff-Ferrari HA, Bruyere O, Cooper C, Cutolo M et al. Vitamin D supplementation in the prevention and management of major chronic diseases not related to mineral homeostasis in adults: research for evidence and a scientific statement from the European society for clinical and economic aspects of osteoporosis and osteoarthritis (ESCEO). *Endocrine* 2017; 56: 245–261. <https://doi.org/10.1007/s12020-017-1290-9> PMID: 28390010
295. Engelman CD, Meyers KJ, Iyengar SK, Liu Z, Karki CK, Igo RP et al. Vitamin D Intake and Season Modify the Effects of the GC and CYP2R1 Genes on 25-Hydroxyvitamin D Concentrations. *J Nutr* 2013; 143: 17–26. <https://doi.org/10.3945/jn.112.169482> PMID: 23190755
296. Hyppönen E, Power C. Hypovitaminosis D in British adults at age 45 y: nationwide cohort study of dietary and lifestyle predictors. *Am J Clin Nutr* 2007; 85: 860–868. PMID: 17344510
297. Kroll MH, Bi C, Garber CC, Kaufman HW, Liu D, Caston-Balderrama A et al. Temporal Relationship between Vitamin D Status and Parathyroid Hormone in the United States. *PLoS ONE* 2015; 10: e0118108. <https://doi.org/10.1371/journal.pone.0118108> PMID: 25738588
298. Fernandes de Abreu DA, Landel V+, F+@ron F. Seasonal, gestational and postnatal influences on multiple sclerosis: The beneficial role of a vitamin D supplementation during early life. *Journal of the Neurological Sciences* 2011; 311: 64–68. <https://doi.org/10.1016/j.jns.2011.08.044> PMID: 21930286
299. Bendik I, Friedel ASJ, Roos FF, Weber P, Eggersdorfer M. Vitamin D: a critical and essential micronutrient for human health. *Frontiers in Physiology* 2014; 5.
300. Hill AB. The Environment and Disease: Association or Causation? *Proc R Soc Med* 1965; 58: 295–300. PMID: 14283879
301. Cashman KD, Dowling KG, Skrabáňková Z, Kiely M, Lamberg-Allardt C, Durazo-Arvizu RA et al. Standardizing serum 25-hydroxyvitamin D data from four Nordic population samples using the Vitamin D Standardization Program protocols: Shedding new light on vitamin D status in Nordic individuals. *Scand J Clin Lab Invest* 2015; 75: 549–561. <https://doi.org/10.3109/00365513.2015.1057898> PMID: 26305421
302. Cashman KD, Kiely M, Kinsella M, Durazo-Arvizu RA, Tian L, Zhang Y et al. Evaluation of Vitamin D Standardization Program protocols for standardizing serum 25-hydroxyvitamin D data: a case study of

- the program's potential for national nutrition and health surveys. *Am J Clin Nutr* 2013; 97: 1235–1242. <https://doi.org/10.3945/ajcn.112.057182> PMID: 23615829
303. Sarafin K, Durazo-Arvizu Rn, Tian L, Phinney KW, Tai S, Camara JE et al. Standardizing 25-hydroxy-vitamin D values from the Canadian Health Measures Survey. *Am J Clin Nutr* 2015; 102: 1044–1050. <https://doi.org/10.3945/ajcn.114.103689> PMID: 26423385
304. Sempas CT, Durazo-Arvizu RA, Carter GD. Cost effective measures to standardize serum 25(OH)D values from completed studies. *Osteoporos Int* 2017; 28: 1503–1505. <https://doi.org/10.1007/s00198-017-3978-3> PMID: 28321505
305. Binkley N, Dawson-Hughes B, Durazo-Arvizu R, Thamm M, Tian L, Merkel JM et al. Vitamin D measurement standardization: The way out of the chaos. *J Steroid Biochem Mol Biol* 2016; Epub ahead of print.